Children's Hospital Medical Center and Affiliates

Title 2 U.S. Code of Federal Regulations Part
200 (Uniform Guidance) Reports for the
Year Ended June 30, 2021

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

Deloitte.

Deloitte & Touche LLP
50 W 5th Street
Suite 200
Cincinnati, OH 45202-3789
USA

Tel: +513 784 7100
Fax: +513 784 7204
www.deloitte.com

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates:
Cincinnati, Ohio

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's and Affiliates"), which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cincinnati Children's as of June 30, 2021 and 2020, and the consolidated results of their operations and their consolidated cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2021 on our consideration of Cincinnati Children's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on Cincinnati Children's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control over financial reporting and compliance.

Deloitte & Touche LLP

September 30, 2021

Children's Hospital Medical Center and Affiliates

Consolidated Balance Sheets
June 30, 2021 and 2020 (dollars in thousands)

	2021	2020
CURRENT ASSETS:		
Cash and cash equivalents	$ 274,863	$ 274,854
Marketable securities	1,352,918	1,028,382
Cash, cash equivalents and marketable securities	1,627,781	1,303,236
Patient receivables, net	506,944	417,654
Other receivables	140,916	134,337
Inventories and prepaid expenses	74,042	47,202
Total current assets	2,349,683	1,902,429
ASSETS LIMITED AS TO USE - Funds in trust	31,250	100,469
PROPERTY AND EQUIPMENT, net of accumulated depreciation	1,403,713	1,310,805
GOODWILL	8,154	-
OPERATING LEASE RIGHT-OF-USE ASSETS	16,485	14,802
PENSION BENEFIT ASSET	171,709	-
OTHER LONG-TERM ASSETS	48,651	52,330
INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS	4,545,670	3,425,051
Total assets	$8,575,315	$6,805,886
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	$ 410,481	$ 332,100
Current portion of long-term debt and lease obligations	28,815	26,509
Commercial paper	100,000	100,000
Bonds payable subject to remarketing, net	91,640	96,774
Total current liabilities	630,936	555,383
ACCRUED PENSION BENEFIT LIABILITY	-	78,931
SELF-INSURANCE RESERVES	22,184	20,666
LONG-TERM DEBT:		
Tax-exempt bonds payable	340,776	358,965
Taxable bonds payable	595,946	397,180
Notes payable	-	6,000
Finance lease obligations	51,647	52,250
Operating lease obligations	14,242	12,978
OTHER LONG-TERM LIABILITIES	54,976	51,117
Total liabilities	1,710,707	1,533,470
COMMITMENTS AND CONTINGENCIES (Note 11)	-	-
NET ASSETS:		
Without donor restrictions	2,100,516	1,655,768
With donor restrictions	4,764,092	3,616,648
Total net assets	6,864,608	5,272,416
Total liabilities and net assets	$8,575,315	$6,805,886

See accompanying notes to consolidated financial statements.

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets
For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

	2021	2020
OPERATING REVENUES, GAINS AND OTHER SUPPORT:		
Net patient service revenue	$2,226,690	$2,060,167
Net assets released from restriction used for operations-		
Grant revenue	202,492	186,594
Other restricted net assets used to support operations	109,627	104,907
Other revenue	207,082	220,386
Total operating revenues, gains and other support	2,745,891	2,572,054
OPERATING EXPENSES:		
Salaries	1,258,656	1,205,925
Employee benefits	347,711	324,118
Supplies, drugs and other	469,344	430,167
Purchased services	252,208	249,333
Depreciation	138,638	130,347
Utilities	18,401	19,177
Interest	23,249	24,627
Total operating expenses	2,508,207	2,383,694
Operating income	237,684	188,360
NONOPERATING GAINS:		
Net investment return	85,743	47,673
Net benefit gain other than service cost	1,682	4,594
Net nonoperating gains	87,425	52,267
Revenue and gains in excess of expenses and losses	325,109	240,627
OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS:		
Receipts from supporting organizations	3,757	3,475
Net assets released from restrictions used for purchase of property and equipment	4,031	968
Transfers to supporting organizations	(37,181)	(108,625)
Pension and post-retirement health liability adjustment	149,032	(80,752)
Increase in net assets without donor restrictions	$ 444,748	$ 55,693

(Continued on next page)

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets
For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

	2021	2020
NET ASSETS WITH DONOR RESTRICTIONS:		
Contributions and investment income-		
Grant receipts	$ 202,702	$ 186,761
Gifts, contributions and other income	140,273	125,605
	342,975	312,366
Net assets released from restriction-		
Grant expenditures	(202,492)	(186,594)
Net assets with donor restrictions used to support operations	(109,627)	(104,907)
Net assets with donor restrictions used for purchase of property and equipment	(4,031)	(968)
	(316,150)	(292,469)
Gain (loss) in interest in net assets of supporting organizations	1,120,619	(1,888)
Increase in net assets with donor restrictions	1,147,444	18,009
INCREASE IN NET ASSETS	1,592,192	73,702
NET ASSETS, beginning of year	5,272,416	5,190,063
Cumulative effect of adoption of ASU 2016-02	-	8,651
ADJUSTED NET ASSETS, beginning of year	5,272,416	5,198,714
NET ASSETS, end of year	$6,864,608	$5,272,416

See accompanying notes to consolidated financial statements.

Children’s Hospital Medical Center and Affiliates

Consolidated Statements of Cash Flows
For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	$ 1,592,192	$ 73,702
Adjustments to reconcile increase in net assets to net cash provided by operating activities-		
Depreciation and amortization	135,955	128,714
Loss on disposal of property and equipment	1,563	3,550
Proceeds from sale of donated securities	2,176	2,285
Receipts from supporting organizations	(3,757)	(3,475)
Contributions to supporting organizations	37,181	108,625
Contributions restricted for purchase of property and equipment	(4,031)	(968)
(Gain) loss in interest in net assets of supporting organizations	(1,120,619)	1,888
Unrealized and realized gains on marketable securities, net	(50,232)	(24,811)
(Gain) loss on interest rate swap	(3,066)	6,022
(Increase) decrease in receivables	(95,869)	22,446
Increase in inventories and prepaid expenses and other assets	(23,161)	(3,845)
(Increase) decrease in pension benefit asset	(250,640)	99,930
Increase in accounts payable and accrued expenses, net	71,877	20,179
Decrease in operating lease obligations	(2,097)	(2,353)
Increase (decrease) in self-insurance reserves and other long-term liabilities	8,443	(1,397)
Net cash provided by operating activities	295,915	430,492
CASH FLOWS FROM INVESTING ACTIVITIES:		
Expenditures for property and equipment	(220,455)	(239,876)
Acquisition of pediatric primary care practices	(8,583)	-
Purchases of marketable securities	(1,484,503)	(2,186,563)
Sales and maturities of marketable securities	1,208,023	2,131,953
Cash withdrawn from funds in trust	1,391	3,670
Cash invested in funds in trust	(8,526)	(14,987)
Net cash used in investing activities	(512,653)	(305,803)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Issuance of bonds and notes payable	200,000	200,000
Repayment of bonds, notes payable, and finance lease obligations	(30,214)	(35,651)
Contributions restricted for purchase of property and equipment	4,031	968
Receipts from supporting organizations	3,757	3,475
Contributions to supporting organizations	(37,181)	(108,625)
Net cash provided by financing activities	140,393	60,167
Net (decrease) increase in cash, cash equivalents, and restricted cash	(76,345)	184,856
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year	359,247	174,391
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year	$ 282,902	$ 359,247
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:		
Capital expenditures in accounts payable and accrued expenses	$ 29,882	$ 23,378
Acquisition of property through finance leases	$ 5,793	$ -
Acquisition of property through operating leases	$ 3,906	$ 3,575

See accompanying notes to consolidated financial statements.

(1) Accounting Policies –

(a) Basis of Consolidation – Children’s Hospital Medical Center (Cincinnati Children’s), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), Burnet Ave LLC (Burnet), TSHCH LLC (TSHCH), DTPM2 LLC (DTPM2), BACE Properties LLC (BACE) and Avondale Rentals LLC (Avondale Rentals), which are under common management, are included in the accompanying consolidated financial statements and are collectively referred to as Cincinnati Children’s. Intercompany transactions and balances have been eliminated.

Cincinnati Children’s is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and related research. River City is a captive insurance company and a wholly owned subsidiary of Cincinnati Children’s. CHSN is a wholly owned subsidiary of Cincinnati Children’s whose purpose is to manage primary care practices in a community setting. Burnet, TSHCH, DTPM2, BACE and Avondale Rentals are wholly owned subsidiaries of Cincinnati Children’s whose purpose is to hold land.

(b) Supporting Organizations – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children’s. Effective March 19, 2021, CHFC changed the name of The Convalescent Hospital for Children and Orphan Asylum (CHCOA) to the Convalescent Hospital Fund for Children.

The TCH and CHFC purpose clauses both specify the support of Cincinnati Children’s as the organization’s sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children’s. As such, the assets of TCH and CHFC are recorded in Cincinnati Children’s consolidated financial statements as an increase in Interest in Net Assets of Supporting Organizations and an increase in Net Assets with Donor Restrictions. Changes in the fair value of Interest in Net Assets of Supporting Organizations are recorded as a Gain in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations’ Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts, contributions and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts are from TCH as designated by the supporting organization’s Board of Trustees to provide general support. The receipts are reflected in Receipts from supporting organizations without donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(c) Support Received from Supporting Organizations – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The Supporting Organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In January 2020, CHFC's Board of Trustees made a gift in the amount of $36,000 to support the construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children's *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children's is entitled to the assets promised. A contribution of $1,855 was made for the year ended June 30, 2021. The receipts are reflected in Gifts, contributions and other income with donor restrictions and in Net assets used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

The following table details transfers between Cincinnati Children's and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

	2021	2020
Transfers of net assets with donor restrictions included in Gifts, contributions and other income:		
Cincinnati Children's from TCH	$ 103,074	$ 88,274
Cincinnati Children's from CHFC	6,280	3,867
Total	109,354	92,141
Transfers of net assets without donor restrictions included in Receipts from (Transfers to) supporting organizations:		
Cincinnati Children's from TCH	3,757	3,475
Cincinnati Children's to TCH (1)	(37,181)	(108,625)
Total	(33,424)	(105,150)
Receivables at June 30		
Cincinnati Children's from TCH (2)	-	10,587
Total	$ -	$ 10,587

(1) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.
(2) This receivable relates to an expected payment upon the maturity of a life insurance policy. The policy matured in fiscal year 2021, and proceeds were transferred to Cincinnati Children's.

(d) Revenue Recognition – The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) "Revenue from Contracts with Customers":

	2021	2020
Net patient service revenue	$2,226,690	$2,060,167
Other revenue	207,082	220,386
	$2,433,772	$2,280,553

Net Patient Service Revenue
Cincinnati Children's net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously receive and consume the benefits of health care provided by Cincinnati Children's, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Effective January 1, 2021, Cincinnati Children's signed an agreement with an Ohio Medicaid managed care company in which performance obligations are to stand-ready to provide care for approximately 130,000 children. The performance obligation to stand-ready is satisfied over time. Cincinnati Children's is reimbursed under a variable capitation methodology for hospital services. All physician and home care services are reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children's physician services, (b) Cincinnati Children's home care services, (c) services provided to members by facilities outside the Cincinnati Children's network, and (d) an actuarially determined accrual for incurred but not reported claims (see Note 1h). Under delegation agreements, Cincinnati Children's receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded in fiscal year 2021 under this arrangement is $103,836.

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children's. In addition, the contracts Cincinnati Children's has with third party payers also provide for retroactive audit and review of claims. At June 30, 2021, Cincinnati Children's has settled all Medicaid cost reports through 2016 and all Medicare cost reports through 2019.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2021 and 2020.

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

In both fiscal years 2021 and 2020, substantially all of net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children's classifies its patients by payer. The following table disaggregates Cincinnati Children's net patient service revenue by payer categories for the fiscal year ended June 30, 2021 and 2020:

	2021		2020	
Commercial insurers	1%	$ 22,266	2%	$ 41,203
Managed care	63%	1,402,815	65%	1,339,108
Government (HMO and third party)	28%	623,473	25%	515,042
International	4%	89,068	3%	61,805
Specialty contracts[1]	3%	66,801	4%	82,407
Self-pay	1%	22,267	1%	20,602
		$2,226,690		$2,060,167

The following details the percentage of accounts receivable by payer category as of June 30, 2021 and 2020:

	2021	2020
Commercial insurers	2%	3%
Managed care	63%	57%
Government (HMO and third party)	20%	22%
International	7%	9%
Specialty contracts[1]	7%	7%
Self-pay	1%	2%

[1] Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

Other Revenue
Cincinnati Children's other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services. Relief funds received as a result of the Coronavirus Aid, Relief, and Economic Security (CARES) Act are also included in other revenue. See Note 1(s) for further discussion on the COVID-19 Pandemic.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children's patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

(e) Graduate Medical Education – Cincinnati Children's receives Federal graduate medical education funding. Other revenue of $11,188 and $10,832 was recognized for the years ended June 30, 2021 and 2020, respectively.

(f) Tax Exempt Status – Cincinnati Children's and CHSN are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. Burnet, TSHCH, DTPM2, BACE and Avondale Rentals are limited liability corporations whose income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying consolidated financial statements are immaterial for the years ended June 30, 2021 and 2020.

Cincinnati Children's accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is Cincinnati Children's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2021 and 2020.

Fiscal years 2018 through 2021 are subject to examination by both the Federal and State tax jurisdictions.

(g) Cash Equivalents – Cash equivalents consist primarily of money market investments (including money market mutual funds) and demand deposits. Money market investments have maturities of 90 days or less at the time of purchase. Cash is held primarily in two financial institutions.

(h) Inventories and Prepaid Expenses – Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

As part of Cincinnati Children's variable capitation agreement, reimbursement is reduced by an actuarially determined estimate for incurred but not reported claims. Cincinnati Children's recorded incurred but not reported claims of approximately $21,107 for the year ended June 30, 2021. The estimate is recorded as an increase in prepaid expenses and an increase in accounts payable and accrued expenses.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(i) Marketable Securities – Cincinnati Children's accounts for its investments under ASC 958-320 "Not-for-Profit Entities – Investments – Debt Securities" and ASC 958-321 "Not-for-Profit Entities – Investments – Equity Securities." Cincinnati Children's carries its marketable securities at fair value with unrealized gains and losses included in investment income in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

At June 30, 2021 and 2020, Cincinnati Children's marketable securities included 19% and 20% in U.S. Treasury securities, respectively.

(j) Property and Equipment – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land Improvements	3-25 years
Buildings and Building Improvements	5-40 years
Equipment	3-25 years

Cincinnati Children's evaluates long-lived assets under the provisions of ASC 360 "Property Plant and Equipment." During fiscal years 2021 and 2020, Cincinnati Children's did not incur any losses related to impairment of property and equipment.

(k) Goodwill – Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children's acquired the assets of a pediatric primary care practice, resulting in goodwill of $8,583 in fiscal year 2021, and elected to apply the accounting alternatives available for not-for-profit entities. Goodwill is amortized over a 10-year period and tested for impairment when a triggering event occurs. During fiscal year 2021, $429 of amortization expense and no impairment losses were recognized.

(l) Leases – Cincinnati Children's leases property and equipment under finance and operating leases. Cincinnati Children's determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children's uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children's leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children's uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

The current portion of operating lease obligations is included in the current portion of long-term debt and lease obligations and the non-current portion is separately stated as operating lease obligations on the consolidated balance sheets. The related right-of-use assets are included in operating lease right-of-use assets on the consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in purchased services in the consolidated statements of operations and changes in net assets.

The current portion of finance lease obligations is included in current portion of long-term debt and lease obligations and the non-current portion is separately broken out as finance lease obligations on the consolidated balance sheets. The related finance lease right-of-use assets are included in property and equipment, net on the consolidated balance sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in depreciation in the consolidated statements of operations and changes in net assets.

(m) Costs of Borrowing – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2021 and 2020, Cincinnati Children's capitalized $11,013 and $6,201 of interest related to construction in progress, respectively. Total cash paid for interest was approximately $33,655 and $30,130 and in fiscal years 2021 and 2020, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

(n) Interest Rate Swap Agreement – In fiscal year 2020, Cincinnati Children's entered into an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within other long-term liabilities. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as non-operating gains and losses within net investment return on the Consolidated Statements of Operations and Changes in Net Assets.

(o) Net Asset Classifications – Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as net assets without donor restrictions. These net assets may be used at the discretion of management of Cincinnati Children's.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors or supporting organizations are classified as net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

(Continued on next page)

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Net assets with donor restrictions are comprised of the following:

	2021	2020
Subject to expenditure for specified purpose:		
Clinical	$ 40,342	$ 36,377
Research	93,558	89,846
Education	16,493	15,344
General Administration and Other	44,831	23,366
	195,224	164,933
Subject to expenditure for specified purpose, held at supporting organizations:		
Research	15,507	11,874
Education	1,144	876
General Administration and Other	4,604	3,526
	21,255	16,276
Subject to expenditure based on Board discretion of the supporting organization, held at supporting organizations	2,202,814	1,648,127
	2,202,814	1,648,127
Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children's:		
Clinical	917	381
Research	17,929	12,803
Education	1,352	999
General Administration and Other	3,000	1,893
	23,198	16,076
Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations:		
Clinical	46,872	34,946
Research	2,099,458	1,589,092
Education	91,815	70,207
General Administration and Other	81,498	60,430
	2,319,643	1,754,675
Subject to appropriation and expenditure when a specified event occurs:		
Upon death of insured party	1,958	16,561
	1,958	16,561
Total net assets with donor restrictions	**$4,764,092**	**$3,616,648**

(Continued on next page)

(p) Revenue and Gains in Excess of Expenses and Losses – The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses and losses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and post-retirement health liability adjustments, and net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses and losses.

(q) Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(r) New Accounting Pronouncements – In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02 *Leases*. ASU 2016-02 introduces a new lessee model that brings substantially all lease obligations and assets onto the balance sheet. Most of the existing lessor principles are retained, but ASU 2016-02 aligns many of those principles with the FASB's new revenue guidance. Cincinnati Children's adopted ASU 2016-02 on July 1, 2019. Cincinnati Children's elected the transition package of practical expedients available in ASU 2016-02 whereby, upon adoption, an entity need not reassess expired or existing contracts to determine whether the contracts are or contain leases or to determine lease classification. Cincinnati Children's additionally elected the short-term lease recognition exemption, a practical expedient which permits a lessee not to recognize on its balance sheet assets and liabilities related to leases whose lease term is twelve months or less. The impact of adoption on the consolidated financial statements on July 1, 2019 resulted in an increase in other noncurrent assets to record right-of-use assets and an increase in other current and noncurrent liabilities to record lease obligations for operating leases of approximately $13,748 representing the present value of remaining lease payments of the operating leases. Additionally, Cincinnati Children's recorded a credit to beginning net assets without restriction of $8,651 for the year ended June 30, 2020. The adoption of ASU 2016-02 did not have a material impact on the consolidated statements of operations and changes in net assets or consolidated statements of cash flows.

In August 2018, the FASB issued ASU 2018-13 *Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*. The ASU improves the effectiveness of the notes to financial statements through changes to disclosure requirements for fair value measurement. The ASU is effective for fiscal years beginning after December 15, 2019 with retrospective application. Cincinnati Children's adopted the standard for the year ended June 30, 2021, and there was no significant impact to the consolidated financial statements as a result of adoption.

In August 2018, the FASB issued ASU 2018-15, *Intangibles—Goodwill and Other (Topic 350): Internal-Use Software.* This standard aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2020, which means that it will be effective for Cincinnati Children's in the fiscal year beginning July 1, 2021. Cincinnati Children's is currently evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This ASU changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022, with early adoption permitted. Cincinnati Children's is currently evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

In March 2021, the FASB issued ASU 2021-03, *Intangibles—Goodwill and Other (Topic 350): Accounting Alternative for Evaluating Triggering Events.* The standard allows not-for-profit entities with an accounting alternative to evaluate the facts and circumstances as of the end of each reporting period to determine whether a triggering event exists and, if so, whether it is more likely than not that goodwill is impaired. An entity that elects this alternative is not required to monitor for goodwill impairment triggering events during the reporting period. The ASU is effective on a prospective basis for fiscal years beginning after December 15, 2019. Cincinnati Children's adopted ASU 2021-03 effective July 1, 2020. Adopting ASU 2021-03 had no impact on the consolidated financial statements.

(s) COVID-19 Pandemic – An order was issued by the Ohio Department of Health, effective Wednesday, March 18, 2020, that required all non-essential or elective surgeries and procedures that utilized personal protective equipment ("PPE") be cancelled. As a result of this order, Cincinnati Children's experienced a decline in patient volumes which significantly affected financial results for fiscal year 2020. This order was rescinded effective April 30, 2020. On May 1, Cincinnati Children's began its "Responsible Recovery for Kids" plan, which included the rescheduling of previously cancelled procedures and reopening outpatient clinics in a gradual, thoughtful, and safe manner. Cincinnati Children's experienced a significant decline in inpatient days, outpatient visits and surgical cases during the period the order was in effect. The financial impact of these declines are reflected in the Consolidated Statement of Operations and Changes in Net Assets for fiscal year 2020.

The Coronavirus Aid, Relief, and Economic Security ("CARES") Act was passed by Congress on March 27, 2020 to aid organization and individuals with the economic impacts of COVID-19. Cincinnati Children's received $50,000 and $42,404 in relief funds from the Department of Health and Human Services in fiscal years 2021 and 2020, respectively. Relief funds are recorded as other revenue in the Operating revenues, gains and other support section of the Consolidated Statements of Operations and Changes in Net Assets for the years ended June 30, 2021 and 2020.

In addition to the distribution of relief funds, the CARES Act also included electable payroll tax credits and deferrals. Cincinnati Children's elected to delay payment of the employer portion of the Social Security payroll taxes on wages paid from March 27, 2020 through December 31, 2020 in the amount of $45,656. Half of the total deferred amount is required to be paid by December 31, 2021 and the remaining portion is due by December 31, 2022. At June 30, 2021, deferred payroll taxes of $22,828 are included in Other Long-Term Liabilities, and $22,828 are included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. At June 30, 2020, deferred payroll taxes totaled $17,013 in Other Long-Term Liabilities.

A payroll tax credit was also available under the CARES Act for employers that continued to pay their employees while experiencing significant declines in operations caused by government orders or mandates associated with the response to the COVID-19 pandemic. The available credit was determined by the amount of eligible wages and healthcare benefits paid to non-working employees. Cincinnati Children's recognized total credits $10,566 in fiscal year 2020, which is reflected as a reduction in the respective Salaries and Employee benefits expenses in the Consolidated Statements of Operations and Changes in Net Assets. No such credits were recognized in fiscal year 2021.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

	2021	2020
Amounts available for general expenditure		
Cash and cash equivalents	$ 274,863	$ 274,854
Marketable securities	1,352,918	1,028,382
Patient receivables, net	506,944	417,654
Other receivables	140,916	134,337
	2,275,641	1,855,227
Less: Board-designated assets	100,000	-
Financial assets available for general expenditure	$2,175,641	$1,855,227

Cincinnati Children's has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal 2021, the Board of Trustees designated $100,000 from net assets without donor restrictions to be used to support Cincinnati Children's community pillar of the *Pursuing Our Potential Together* strategic plan. Cincinnati Children's has other assets limited to use for professional liability, self-insurance health care and debt service, as well as perpetual endowments with donor restrictions. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

Cincinnati Children's has $192,165 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children's maintains certain balances in cash and investments and has access to a $100,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children's is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2021 and 2020, Cincinnati Children's was in compliance with all such covenants.

Cincinnati Children's forecasts its future cash flows and monitors liquidity on an ongoing basis.

(3) Reconciliation of Cash, Cash Equivalents, and Restricted Cash –

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2021 and 2020:

	2021	2020
Cash and cash equivalents	$274,863	$274,854
Restricted cash included in other long-term assets	8,039	84,393
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$282,902	$359,247

(4) Fair Value Measurements –

Cincinnati Children's accounts for its assets and liabilities under ASC 820 "Fair Value Measurements." As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children's estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children's utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

(Continued on next page)

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2021.

	Level 1	Level 2	Level 3	Total
Marketable Securities:				
U.S. Government and agency securities	$ -	$370,368	$ -	$ 370,368
Foreign bonds	-	46,067	-	46,067
Municipal bonds	-	9,347	-	9,347
Common stock	239,044	-	-	239,044
Corporate obligations	-	471,451	-	471,451
Bond mutual funds	25,086	-	-	25,086
Total marketable securities measured in the fair value hierarchy	264,130	897,233	-	1,161,363
Full discretion fixed income				191,555
	264,130	897,233	-	1,352,918
Assets Limited As To Use:				
Money market mutual funds	9,088	-	-	9,088
Common stock	22,162	-	-	22,162
	31,250	-	-	31,250
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	8,116	-	-	8,116
Mutual funds:				
Money market	1,203	-	-	1,203
Equity	950	-	-	950
International equity	587	-	-	587
Bond	972	-	-	972
Lifecycle	3,384	-	-	3,384
Variable annuities	-	208	-	208
Guaranteed insurance contract	-	-	469	469
	15,212	208	469	15,889
Derivative Investments (included in Other-Long-term Liabilities):				
Interest rate swap agreement	-	(2,956)	-	(2,956)
Total investments at fair value	$310,592	$894,485	$469	$1,397,101

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2020.

	Level 1	Level 2	Level 3	Total
Marketable Securities:				
U.S. Government and agency securities	$ -	$352,525	$ -	$352,525
Foreign bonds	-	31,853	-	31,853
Municipal bonds	-	8,338	-	8,338
Common stock	118,316	-	-	118,316
Corporate obligations	-	374,481	-	374,481
Total marketable securities measured in the fair value hierarchy	118,316	767,197	-	885,513
Full discretion fixed income				82,952
High yield corporate obligations				59,917
	118,316	767,197	-	1,028,382
Assets Limited As To Use:				
Money market mutual funds	84,527	-	-	84,527
Common stock	15,942	-	-	15,942
	100,469	-	-	100,469
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	5,967	-	-	5,967
Mutual funds:				
Money market	286	-	-	286
Equity	956	-	-	956
International equity	384	-	-	384
Bond	776	-	-	776
Lifecycle	3,916	-	-	3,916
Variable annuities	-	101	-	101
Guaranteed insurance contract	-	-	1,737	1,737
	12,285	101	1,737	14,123
Derivative Investments (included in Other-Long-term Liabilities):				
Interest rate swap agreement	-	(6,022)	-	(6,022)
Total investments at fair value	$231,070	$761,276	$1,737	$1,136,952

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Cincinnati Children's uses quoted market prices in active markets to determine the fair value of common stock and mutual funds; such items are classified as Level 1 in the fair value hierarchy.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Cincinnati Children's primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children's interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

Cincinnati Children's investment in High Yield Corporate Obligations is an investment in a limited liability company whose investment objective is to achieve superior fixed income returns on invested funds through exposure to higher quality, less volatile, high yield debt securities. As set forth in the LLC agreement, the LLC will dissolve on March 29, 2040, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC on the last business day of any month or at such other date, as determined by the manager. The High Yield Corporate Obligations is measured at fair value using the net asset value per share practical expedient.

Cincinnati Children's investment in Full Discretion Fixed Income is an investment in a limited liability company whose investment objective is to invest in marketable and non-marketable securities with issue and industry diversification. As set forth in the LLC agreement, the LLC will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC if the Member notifies of intent to withdraw sixty calendar days in advance. The Full Discretion Fixed Income is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

2021	Guaranteed Insurance Contracts
Purchases	$132
Issues	-

2020	Guaranteed Insurance Contracts
Purchases	$257
Issues	-

Cincinnati Children's policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2021 and 2020, there were no material transfers in or out of Levels 1, 2 or 3.

(5) Losses on the Provision of Uncompensated Care –

In accordance with its mission and purpose, Cincinnati Children's maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children's accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children's defines uncompensated care as services rendered to patients whose families' annual income or net worth falls below certain minimum standards. As such, losses absorbed by Cincinnati Children's in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The following information summarizes uncompensated care provided during the years ended June 30, 2021 and 2020:

CHARGES	**2021**	**2020**
Charges under Medicaid and other entitlement programs	$1,982,947	$1,877,045
Charity care not eligible for Medicaid assistance, at established charges	24,580	29,606
Other uncollectible self-pay, at established charges	19,442	27,404
Total Medicaid, charity care and other uncollectible self-pay charges	$2,026,969	$1,934,055
COSTS/LOSSES		
Estimated costs to provide uncompensated care	$ 851,532	$ 817,078
Reimbursement from Medicaid programs	(611,230)	(493,257)
Losses on the provision of uncompensated care	(240,302)	(323,821)
Funds received from HCAP and tax levy	31,463	31,039
Losses on provision of uncompensated care net of HCAP and tax levy	$(208,839)	$(292,782)

The 2021 and 2020 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust –

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

	June 30,	
	2021	**2020**
Self-insurance Funds-		
Professional liability	$ 159	$ 160
Employee health and workers' compensation	140	140
Bond interest and principle escrow funds	7,740	6,960
Endowment funds held in perpetual trust	23,211	16,076
Bond proceeds held in trust for construction project	-	77,133
	$31,250	$100,469

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(7) Property and Equipment –

Property and equipment consists of the following:

	June 30, 2021	June 30, 2020
Land	$ 42,158	$ 42,142
Land improvements	31,645	32,038
Buildings and building improvements	1,610,173	1,599,462
Equipment	693,081	678,044
Construction in progress	416,644	273,169
	2,793,701	2,624,855
Accumulated depreciation	(1,389,988)	(1,314,050)
Property and equipment, net	$1,403,713	$1,310,805

(8) Professional Liability –

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is $10,000 ($25,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claim made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of $22,184 and $20,939 for 2021 and 2020, respectively, has been accrued in the accompanying Consolidated Balance Sheets. Accrued healthcare professional liability losses have been discounted at a rate of 4% at June 30, 2021 and 2020. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense was $5,359 and $12,309 for fiscal years 2021 and 2020, respectively.

(Continued on next page)

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(9) Debt –

Debt at June 30, 2021 and 2020 is summarized as follows:

	2021	2020
Series 2018BB commercial paper, variable interest (0.04% to 0.08% at June 30, 2021), taxable	$100,000	$100,000
Bonds payable:		
Series 2011, 2.18% due through 2023	8,480	16,555
Series 2014S, 3.0% to 5.0% due through 2034, net of unamortized premium of $2,662 in 2021 and $3,437 in 2020	92,029	98,324
Series 2014T, 4.268% due 2044, taxable	297,804	297,708
Series 2016X, 5.00%, due through 2032, net of unamortized premium of $8,744 in 2021 and $9,540 in 2020	59,937	60,687
Series 2016Y, 2.853% due 2026, taxable	99,558	99,472
Series 2018Z*, variable interest (0.03% at June 30, 2021), due through 2037	36,012	38,029
Series 2018AA*, variable interest (0.03% at June 30, 2021), due through 2037	55,627	58,745
Series 2019CC, 5.0% due through 2049, net of unamortized premium of $60,360 in 2021 and $62,793 in 2020	194,715	197,099
Series 2020DD, 2.82% due 2051, taxable	198,585	-
Notes Payable:		
Term Note Payable, 2.20% due 2022	6,000	12,000
Total	1,148,747	978,619
Less:		
Current portion of bonds and notes payable	(20,385)	(19,700)
Commercial paper notes	(100,000)	(100,000)
Bonds payable subject to remarketing, net	(91,640)	(96,774)
Bonds payable and notes payable - long-term	$936,722	$762,145

*Denotes variable rate bonds subject to remarketing agreements

(a) Bonds Payable – Cincinnati Children's has pledged gross revenues to secure the payment of 2011, 2014S, 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, and 2020DD bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, direct placement agreements, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as current liabilities in bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

(b) Commercial Paper – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of $100,000 and outstanding at any one time in a principal amount not to exceed $100,000. The Notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been resold, Cincinnati Children's must repay the notes. The 2018BB commercial paper is classified as current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(c) Future Debt Maturities – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

2022	$ 212,550
2023	9,125
2024	9,060
2025	9,510
2026	9,750
Thereafter	833,835
	$1,083,830

(d) Line of Credit – In June 2020, Cincinnati Children's entered into a 1-year agreement for a line of credit of $100,000. The line of credit agreement was amended in June 2021 to extend the maturity date to June 2024. The line of credit bears interest at the greater of the Daily Reset LIBOR Rate or 0.50%, plus 50 basis points. In the event LIBOR is no longer available, the line of credit bears interest at the daily SOFR rate, plus an adjustment spread. There were no draws on the line of credit during fiscal year 2021 or 2020.

(10) Employee Benefit Plans –

Cincinnati Children's maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children's investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Cincinnati Children's adopted an Investment Policy that adjusts allocations between return-seeking assets and liability-hedging assets based on the funded status of the Plan and prevailing yields. As the funded ratio improves, allocations to liability-hedging assets increase accordingly.

Cincinnati Children's seeks to maintain diversified portfolios and has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

Return-Seeking Allocation:	Min - Target -Max
Global Equity	60% - 70% - 80%
Private Equity	5% - 10% - 15%
Private Real Estate	5% - 10% - 15%
Multi-Asset Credit	5% - 10% - 15%
Opportunity Allocation	0% - 0% - 10%
Liability-Hedging Allocation:	
Long Credit	50% - 75% - 100%
STRIPS (Long Duration Treasury Instruments)	0% - 25% - 50%

In order to maintain the portfolio's actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically. As of June 30, 2021, Cincinnati Children's has made $126,400 in funding commitments in eleven investment partnerships of which $81,340 has been funded. Additionally, Cincinnati Children's has made $72,500 in funding commitments in nine real estate investment partnerships of which $67,620 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2021 and 2020 by asset category is as follows:

	2021	**2020**
Cash and cash equivalents	1.7%	1.8%
Corporate bonds	13.6%	16.4%
Government bonds	1.8%	1.1%
Investment Partnerships:		
Equity	4.0%	4.0%
Bond	0.8%	6.4%
Real estate	2.4%	2.9%
Commingled Investment Funds		
Equity	18.7%	35.8%
Bond	40.0%	19.3%
Government	17.0%	12.3%
	100.0%	100.0%

At June 30, 2021, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$29,579	$ -	$ -	$ 29,579
Corporate bonds	-	239,259	-	239,259
Government bonds	-	31,870	-	31,870
Total assets in the fair value hierarchy	29,579	271,129	-	300,708
Investments measured at net asset value[1]:				
Investment Partnerships:				
Equity	-	-	-	70,552
Bond	-	-	-	14,348
Real Estate	-	-	-	42,696
Commingled Investment Funds:				
Equity	-	-	-	327,271
Bond	-	-	-	702,807
Government	-	-	-	297,274
Total assets at fair value	$29,579	$271,129	$ -	$1,755,656

(Continued on next page)

[1] Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheet.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

At June 30, 2020, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	$25,999	$ -	$ -	$ 25,999
Corporate bonds	-	239,216	-	239,216
Government bonds	-	15,899	-	15,899
Total assets in the fair value hierarchy	25,999	255,115	-	281,114
Investments measured at net asset value[1]:				
Investment Partnerships:				
Equity	-	-	-	58,171
Bond	-	-	-	92,715
Real Estate	-	-	-	42,510
Commingled Investment Funds:				
Equity	-	-	-	520,228
Bond	-	-	-	280,657
Government	-	-	-	178,829
Total assets at fair value	$25,999	$255,115	$ -	$1,454,224

The fair values of Level 1 investments are based on quoted prices in active markets. The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy. Investments in partnerships – U.S. equities, real estate, and bonds – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties. Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded equity mutual funds, bond mutual funds, and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2021 or fiscal year 2020.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

	2021	**2020**
Discount rate used to determine actuarial present value of the projected benefit obligation	3.27%	3.33%
Assumed rate of increase in compensation levels	3.50%	3.50%
Long-term rate of return	5.50%	5.50%

[1] Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheet.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2021 and 2020, utilizing actuarial measurement dates as of June 30, 2021 and 2020.

	2021	2020
Change in projected benefit obligation:		
Projected benefit obligation at beginning of year	$1,533,155	$1,338,263
Service cost	71,800	60,340
Interest cost	49,725	50,425
Other actuarial loss	33,202	167,618
Benefits paid	(103,935)	(83,491)
Projected benefit obligation at end of year	$1,583,947	$1,533,155
Change in plan assets:		
Fair value of plan assets at beginning of year	$1,454,224	$1,359,262
Actual gain on plan assets	233,567	141,893
Employer contributions	171,800	36,560
Benefits paid	(103,935)	(83,491)
Fair value of plan assets at end of year	1,755,656	1,454,224
Funded status	171,709	(78,931)
Net accrued pension benefit asset (liability) in Consolidated Balance Sheets	$ 171,709	$ (78,931)

For the Retirement Plan, the overall actuarial loss in plan obligation of approximately $33 million is primarily attributable to a decrease in the discount rate between June 30, 2020 and June 30, 2021. The discount rate decrease of 6 basis points resulted in an increase in benefit obligation of approximately $20 million.

In 2021 and 2020, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial loss in fiscal years 2021 and 2020.

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

	2021	2020
Net actuarial loss	$317,248	$477,831
Net prior service credit	(77,041)	(88,792)
	$240,207	$389,039

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

	2021	2020
Discount rate used to determine benefit costs	3.33%	3.86%
Assumed rate of increase in compensation levels	3.50%	3.50%
Expected long-term rate of return on plan assets	5.50%	5.50%

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Net periodic pension cost for 2021 and 2020 related to the defined benefit plan consisted of the following components:

	2021	2020
Service cost	$71,800	$60,340
Interest cost	49,725	50,425
Return on plan assets	(76,121)	(72,312)
Amortization of prior service credit	(11,751)	(11,751)
Recognized net actuarial loss	36,339	29,357
Net periodic pension cost	$69,992	$56,059

Based on preliminary estimates, we do not expect any required fiscal year 2021 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was $1,504,250 and $1,462,649 at June 30, 2021 and 2020, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

2022	$75,570
2023	74,960
2024	76,977
2025	78,612
2026	80,065
2027-2031	427,085

All other retirement plans maintained by Cincinnati Children's are defined contribution plans. Cincinnati Children's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately $27,581 and $25,862 in fiscal years 2021 and 2020, respectively.

Cincinnati Children's provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children's if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense recognized in fiscal years 2021 and 2020 was $1,358 and $175, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term assets with a corresponding liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2021 and 2020:

	2021	2020
Current portion	$ 307	$ 2,640
Long-term portion	15,582	11,483
Total assets and liabilities	$15,889	$14,123

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The postretirement benefit obligations, included within other long-term liabilities, as of June 30, 2021 and 2020 were as follows:

	2021	2020
Change in benefit obligation:		
Benefit obligation at beginning of year	$1,514	$1,756
Interest cost	26	48
Actuarial gain	(101)	(41)
Benefits paid	(223)	(249)
Benefit obligation at end of year	$1,216	$1,514

Amounts included in Unrestricted Net Assets but not yet recognized in postretirement cost consist of:

	2021	2020
Net actuarial loss	$1,108	$1,402
Net prior service cost	(51)	(144)
	$1,057	$1,258

The above table reflects the following weighted average assumptions to determine postretirement obligations:

	2021	2020
Discount rate	1.88%	1.84%

Net periodic cost for 2021 and 2020 related to the postretirement benefits consisted of the following components:

	2021	2020
Interest cost	$ 26	$ 48
Amortization of unrecognized net gain and prior service credit	100	(362)
	$126	$(314)

For fiscal years 2021 and 2020, the discount rate used to determine the net periodic postretirement costs was 1.84% and 2.98%, respectively.

Cincinnati Children's expects to make the future benefit payments, which reflect expected future service, as appropriate. The following benefit payments are expected to be paid over each of the next five years and five fiscal years thereafter:

	Payments
2022	$188
2023	169
2024	150
2025	132
2026	115
2027-2031	372

(11) Commitments and Contingencies –

(a) Litigation – Cincinnati Children's is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC No. 450, "Contingencies." After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children's.

(b) Laws and Regulations – The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children's is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.

(c) Capital Commitments – In fiscal year 2018, Cincinnati Children's entered into agreements to build and equip a 633,000 square foot clinical building and renovate 146,000 square feet of existing space. Construction commenced in fiscal year 2018. In fiscal year 2020, Cincinnati Children's Board of Trustees approved expanding the renovation scope to a total of 285,000 square feet. Cincinnati Children's has spent approximately $460,782 through June 30, 2021 and expects to spend an additional $237,221 in conjunction with the construction project. The new building will be completed in fiscal year 2022, and the renovation will be completed in fiscal year 2024.

In fiscal year 2020, Cincinnati Children's Board of Trustees approved construction of a replacement facility at the College Hill campus which provides inpatient and outpatient mental health services. The facility is anticipated to be approximately 175,000 square feet. Cincinnati Children's spent $6,846 through June 30, 2021 and expects to spend an additional $92,154 in conjunction with the construction project. The replacement facility is projected to be completed in fiscal year 2024.

In fiscal year 2020, Cincinnati Children's Board of Trustees approved the construction of a new ambulatory facility on the eastside of Cincinnati. This project will consolidate two smaller leased facilities into one larger owned facility. Cincinnati Children's spent $49 through June 30, 2021 and expects to spend an additional $34,951. The new facility is projected to be completed in fiscal year 2025.

Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovation projects, equipment, and information system technology projects. Cincinnati Children's has committed to spend approximately $21,928 in connection with current active projects as of June 30, 2021. The projects are expected to be completed primarily in fiscal year 2022.

(d) Funding Commitments – The Board of Trustees of Cincinnati Children's approved revocable commitments for up to $20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children's has provided $17,867 of funding in relation to these commitments through June 30, 2021. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential projects in the uptown area. During fiscal year 2021, none of the loans were repaid. Cincinnati Children's expects to receive an additional $5,000 related to the loans.

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(e) Investment Commitments – Cincinnati Children's has made commitments to invest $25,000 in five limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children's has made commitments to invest $12,294 in nine limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other Assets in the Consolidated Balance Sheets. Cincinnati Children's occasionally receives distributions from these investments which reduce investment values.

The following displays the amounts funded and investment values at June 30, 2021 and 2020:

2021	Funded	Value
Investment in Limited Partnerships	$20,349	$ 8,075
Investments in Limited Liability Corporations	9,324	13,263
Total	$29,673	$21,338

2020	Funded	Value
Investment in Limited Partnerships	$19,076	$8,841
Investments in Limited Liability Corporations	7,958	8,540
Total	$27,034	$17,381

(12) Leases –

Cincinnati Children's leases certain property and equipment. Cincinnati Children's determines if an arrangement is a lease at inception of a contract.

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2021 and 2020:

	2021	2020
Operating lease expense	$ 2,765	$ 3,236
Finance leases:		
Amortization of right-of-use assets	6,698	6,556
Interest on finance lease obligations	1,955	1,915
Short-term and variable lease expense	4,994	4,494
Total lease expense	$16,412	$16,201

Other information related to leases for the years ended June 30, 2021 and 2020 is as follows:

Supplemental cash flow information

Cash paid for amounts included in the measurement of lease liabilities:

	2021	2020
Operating cash flows from operating leases	$ 2,097	$ 2,353
Financing cash flows from finance leases	5,319	5,621

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Weighted average remaining lease term (in years)

	2021	2020
Operating leases	7.4	8.0
Finance leases	10.5	11.8

Weighted average discount rate

	2021	2020
Operating leases	3.27%	3.61%
Finance leases	3.34%	3.41%

The aggregate future lease payments for operating and finance leases as of June 30, 2021 are as follows:

	Operating	Finance
2022	$ 3,055	$ 7,705
2023	3,081	7,078
2024	3,005	6,331
2025	2,684	6,331
2026	1,691	5,829
Thereafter	5,594	35,499
Total lease payments	19,110	68,773
Present values:		
Current lease liabilities	2,548	5,882
Long-term lease liabilities	14,242	51,647
Total lease liabilities	$16,790	$57,529
Difference between undiscounted cash flows and discounted cash flows	$ 2,320	$11,244

(13) Functional Expenses – The cost of providing Cincinnati Children's services are summarized on a functional basis in the following tables. Accordingly, certain costs have been allocated among functions. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

Expense	Method of Allocation
Employee benefits	Full Time Equivalent
Depreciation	Square footage
Utilities	Square footage

The following presents expenses by both their nature and function for the year ended June 30, 2021:

	Clinical	Research	Education	Fundraising	Management and General	TOTAL
Salaries	$ 814,088	$186,686	$57,395	$4,159	$196,328	$1,258,656
Employee benefits	204,106	51,114	11,822	1,043	79,626	347,711
Supplies, drugs and other	367,962	38,150	1,936	427	60,869	469,344
Purchased services	86,164	42,605	2,258	720	120,461	252,208
Depreciation	82,628	28,282	139	416	27,173	138,638
Utilities	10,967	3,754	18	55	3,607	18,401
Interest	-	-	-	-	23,249	23,249
	$1,565,915	$350,591	$73,568	$6,820	$511,313	$2,508,207

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The following presents expenses by both their nature and function for the year ended June 30, 2020:

	Clinical	Research	Education	Fundraising	Management and General	TOTAL
Salaries	$ 771,653	$182,646	$54,929	$4,236	$192,461	$1,205,925
Employee benefits	189,805	46,366	14,763	1,254	71,930	324,118
Supplies, drugs and other	333,008	32,113	3,266	581	61,199	430,167
Purchased services	83,223	43,344	2,422	568	119,776	249,333
Depreciation	78,555	27,553	116	349	23,774	130,347
Utilities	11,557	4,054	17	51	3,498	19,177
Interest	-	-	-	-	24,627	24,627
	$1,467,801	$336,076	$75,513	$7,039	$497,265	$2,383,694

(14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2021:

Effective	Expiration	Counterparty	Interest Rate Paid	Interest Rate Received	Notational Amount
August 2019	August 2029	Fifth Third Bank	1.38%	USD-SIFMA Municipal Swap Index, 0.03% at June 30th	$92,165,000

(15) Subsequent Events –

Management reviewed subsequent events through September 30, 2021, the date the consolidated financial statements were issued, noting no changes are required to the consolidated financial statements or footnotes.

Children's Hospital Medical Center and Affiliates
Supplementary Schedule of Expenditure of Federal Awards
For the Year Ended June 30, 2021

Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Indentifying Number	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Department of Defense	Military Medical Research and Developmer	Ionic Mechanisms of Resistance to				W81XWH1710378	12.420	$ -	$ 59,372.00	$ 59,372.00
		Stathmin phosphorylation as a	University of Cincinnat		011138-002	W81XWH1710601	12.420	-	$ 5,087.00	5,087.00
		Therapeutic Benefit of Hsp90 Inhibitior		University of Cincinnat		W81XWH1710666	12.420	46,726.00	$ 216,085.00	262,811.00
		Mechanisms of acute pain gene	Biotechnology HPC Software Application		5161	W81XWH1720024	12.420	-	$ 122,458.00	122,458.00
		Neurofibromatosis Clinical Consor	University of Alabama-Birminghan		000516840-004-T001	W81XWH1720037	12.420	-	$ 6,900.00	6,900.00
		A Novel and Rapid System to C		Ohio State University		W81XWH1810269	12.420	33,095.00	$ 238,176.00	271,271.00
		Novel Neuroimaging Assessments				W81XWH1810615	12.420	-	$ 31,373.00	31,373.00
		Surviving and Thriving in the				W81XWH1810677	12.420	-	$ 294,766.00	294,766.00
		Roleof hepatocyte-derived extracellula				W81XWH1910038	12.420	-	$ 31,023.00	31,023.00
		Development of Virtual Surger				W81XWH1910043	12.420	-	$ 103,537.00	103,537.00
		A Novel FANCD2-Chromatin Bounc				W81XWH1910262	12.420	-	$ 194,922.00	194,922.00
		Single cell analyses of NF1 p				W81XWH1910816	12.420	-	$ 272,689.00	272,689.00
		Immune-Schwann cell signaling				W81XWH2010116	12.420	-	$ 129,457.00	129,457.00
		Antioxidant Therapy with N-Ac				W81XWH2010139	12.420	-	$ 221,085.00	221,085.00
		Merlin-ASPP2 Tumor Suppresso				W81XWH2010377	12.420	-	$ 160,526.00	160,526.00
		Inflammatory vigor in heterog				W81XWH2010392	12.420	-	$ 218,923.00	218,923.00
		Inflammatory vigor in heterog				W81XWH2010393	12.420	-	$ 180,338.00	180,338.00
		Identification of cellular he				W81XWH2010443	12.420	-	$ 70,588.00	70,588.00
		The Influence of Social, Educa	Vanderbilt University Medical Cente		VUMC84410	W81XWH2010475	12.420	-	$ 109,016.00	109,016.00
		Mitochondrial ALR protein del				W81XWH2010477	12.420	-	$ 445,530.00	445,530.00
		Rational Targeting Oncogenic K	University of Wisconsin-Madisor		0000000812	W81XWH2010616	12.420	-	$ 124,483.00	124,483.00
		The role of mitochondria in bo				W81XWH2010689	12.420	-	$ 88,986.00	88,986.00
		Evaluating the therapeutic pc				W81XWH2010870	12.420	-	$ 49,771.00	49,771.00
		MBio DARPA Phase II	MBio Diagnostics, Inc.		IS0000364	140D6318C0027	12.RD	-	$ 2,228.00	2,228.00
		DoD/GEIS project on MDRO globa	Georgetown University Medical Cente		411640_GR411625-CCHI	HT001119R0019	12.RD	-	$ 1,203.00	1,203.00
						Military Medical Research and Development Total		**79,821.00**	**3,378,522.00**	**3,458,343.00**
						Department of Defense Total		**79,821.00**	**3,378,522.00**	**3,458,343.00**
Department of Educatior	Education Research, Development and Disseminatic	Longitudinal Evaluation of the Impac	Virginia Commowealth Universit		FP00000519-SA001	R305A160126	84.305	-	1,971.00	1,971.00
		Longitudinal Evaluation of Sti				R305A200028	84.305	-	218,210.00	218,210.00
						Education Research, Development and Dissemination Tota		**-**	**220,181.00**	**220,181.00**
	Research in Special Educatior	Sluggish Cognitive Tempo: Examining it				R305A160064	84.324	-	148,998.00	148,998.00
		Teaching Academic Success Ski				R324A180053	84.324	-	324,853.00	324,853.00
						Research in Special Education Total		**-**	**473,851.00**	**473,851.00**
						Department of Education Total		**-**	**694,032.00**	**694,032.00**
Department of Justice	Crime Victim Assistance	VOCA Mayerson 2020				2020-VOCA-132924253	16.575	-	76,047.00	76,047.00
		VOCA Joining Forces 2020				2020-VOCA-132924265	16.575	-	263,430.00	263,430.00
		VOCA Forensic RN 2020				2020-VOCA-132924224	16.575	-	52,709.00	52,709.00
		VOCA Mayerson 2021				2021-VOCA-133916106	16.575	-	188,827.00	188,827.00
		VOCA Forensic RN 2021				2021-VOCA-133916112	16.575	-	77,251.00	77,251.00
						Crime Victim Assistance Total		**-**	**658,264.00**	**658,264.00**
	Edward Byrne Memorial Justice Assistance Grant Prograr	BJA Police Response Training	The Arc of The United States INC		BJA Police Response Rid	BJA Police Response Ridd	16.738	-	33,537.00	33,537.00
						Edward Byrne Memorial Justice Assistance Grant Program Tota		**-**	**33,537.00**	**33,537.00**
						Department of Justice Total		**-**	**691,801.00**	**691,801.00**
National Science Foundatior	Biological Sciences	NSF/MCB-BSF:Quantitative analysis and mod		University of Cincinnat		1715822	47.074	19,210.00	114,323.00	133,533.00
						Biological Sciences Total		**19,210.00**	**114,323.00**	**133,533.00**
	Engineering Grants	Accelerating Understanding o	Onu Technology, Inc	University of Cincinnat	2028008 NSF	2028008 NSF	47.041	7,015.00	11,685.00	18,700.00
						Engineering Grants Total		**7,015.00**	**11,685.00**	**18,700.00**
						National Science Foundation Total		**26,225.00**	**126,008.00**	**152,233.00**
Department of Energy		Joint Faculty Agreement No. JI	University of Cincinnat		012385-003	4000173601	81.RD	-	76,719.00	76,719.00
						Department of Energy Total		**-**	**76,719.00**	**76,719.00**
Department of Transportatior	Occupant Protection Regional Coordinatio	Occupant Protection Regional Coor	Ohio Department of Healtl		03130014BB0421	03130014BB0421	20.616	-	27,021.00	27,021.00
						Department of Transportation Total		**-**	**27,021.00**	**27,021.00**
Dept of Health and Human Ser	Aging Research	Metabolic alterations in age-asso		University of Cincinnat		R01AG053498	93.866	16,477.00	524,590.00	541,067.00
		Role of skeletal muscle stem c				R01AG059605	93.866	-	351,201.00	351,201.00
		Novel mechanism of intestina				R01AG063967	93.866	-	594,082.00	594,082.00
		A Novel Research Infrastructu	Tulane University		TUL-HSC-556566-18/19	R21AG057983	93.866	-	105,816.00	105,816.00
		IL-31 Regulation of Immunopatl				R21AG059533	93.866	-	49,136.00	49,136.00
		Causal Role of Mitochondrial D				R21AG061408	93.866	-	33,589.00	33,589.00
		Mechanisms in Lamin A functior				R33AG054770	93.866	-	86,151.00	86,151.00
		A Novel Research Infrastructu	Tulane University		TUL-HSC-556566-18/19	R33AG057983	93.866	-	231,026.00	231,026.00
		Homeostasis and function of re				R56AG033057	93.866	-	268,006.00	268,006.00
						Aging Research Total		**16,477.00**	**2,243,597.00**	**2,260,074.00**
	Allergy, Immunology and Transplantation Researc	Immunological identity redefined b		University of Cincinnat		DP1AI131080	93.855	8,987.00	607,258.00	616,245.00
		Maternal microchimerism trans				F32AI145184	93.855	-	63,409.00	63,409.00
		Epithelial antigen presentati				F32AI147591	93.855	-	67,041.00	67,041.00
		ORMDL3 Regulation of Dendritic Cells				K08AI125675	93.855	-	162.00	162.00
		A concept for Gene Therapy fo	Univ of North Carolina at Chapel Hi		5119391	P30AI050410	93.855	-	19,536.00	19,536.00
		Regulation of Gastrointestina				R01AI045898	93.855	-	306,579.00	306,579.00
		Epidemiologic Impact of HPV Va		Indiana University		R01AI104709	93.855	54,051.00	375,062.00	448,646.00
				University of California				19,533.00	-	
		GM-CSF-Induced Metal Sequestra	University of Cincinnat		011636-003	R01AI106269	93.855	-	19,237.00	19,237.00
		Role of BCAP in Regulating Inflamn				R01AI113125	93.855	-	(22,838.00)	(22,838.00)
		L-citrulline and anti-tuberculosis host				R01AI116668	93.855	-	235,370.00	235,370.00
		Maternal Regulatory T cell antigen-spec				R01AI120202	93.855	-	562,031.00	562,031.00
		Innate Mechanisms Reg of Memory TH17				R01AI123176	93.855	-	351,352.00	351,352.00
		A novel lactic acid bacteria-based nor	Ohio State University		R01AI123661	R01AI123661	93.855	-	47,741.00	47,741.00
		Functional immune tolerance to nor				R01AI124657	93.855	-	389,637.00	389,637.00
		Dendritic cell KLF2/Notch Axis and Th2	University of Cincinnat		R01AI126818	R01AI126818	93.855	-	27,369.00	27,369.00
		Role and Regulation of TSLP in Chilc				R01AI127392	93.855	-	672,210.00	672,210.00
		Role of Aiolos in eosinophilic asthm				R01AI130033	93.855	-	729,214.00	729,214.00
		Wimpy antibody isotypes protect agains	University of Cincinnat		R01AI130103	R01AI130103	93.855	-	99,080.00	99,080.00
		FORWARD Study-Food Allergy Outcomes	Northwestern University Medical Schoc		60046645 CCHMC	R01AI130348	93.855	-	130,357.00	130,357.00
		Forward genetic prediction anc	Pennsylvania State Universit		R01AI132692	R01AI132692	93.855	-	50,736.00	50,736.00
		Role of Microbiome in Neonata	The Regents of the Univ of Californi		A18-0659-S001	R01AI138553	93.855	-	55,421.00	55,421.00
		Early life factors, gene-envi	Wake Forest University Health Science		R01AI139126	R01AI139126	93.855	-	25,888.00	25,888.00
		Translational Regulation of CD				R01AI139675	93.855	-	618,015.00	618,015.00
		SLC9A3 regulation of esophage	University of Michigar		SUBK00011618	R01AI140133	93.855	-	43,785.00	43,785.00
		Role of TET1 in airway epithe	University of California-Davis		A20-0494S001	R01AI141569	93.855	-	35,778.00	35,778.00
		Progesterone induced immune m		University of Pennsylvani		R01AI145840	93.855	418,768.00	196,874.00	615,642.00
		COVID-19 Progesterone induced immune m				COVID-19 R01AI145840-02S1	93.855	-	6,912.00	6,912.00
		Rapid, safe suppression of IgE	University of Cincinnat		1R01AI145991-01	R01AI145991	93.855	-	143,227.00	143,227.00
		Targeting natural killer cells		Duke University		R01AI148080	93.855	23,646.00	744,763.00	768,409.00
		Roles of FFAR 3-SCFA axis in T				R01AI148138	93.855	-	618,716.00	618,716.00
		Genomics of Inflammatory Bowe				R01AI148276	93.855	-	461,418.00	461,418.00
		Viral and Cellular Determinan				R01AI150486	93.855	-	331,571.00	331,571.00

	An experimentally-refined, dy				R01AI153442	93.855	-	97,154.00	97,154.00
	Proteasome targeting for allc	University of Pennsylvania		580121	R01AI154932	93.855	-	134,349.00	134,349.00
	Defining the role of Gimap5 in T cell dif				R21AI131050	93.855	-	99,661.00	99,661.00
	Mech of LRBAmediatedcontrol of CTLA4				R21AI132822	93.855	-	114.00	114.00
	The molecular analysis of Gab:				R21AI135380	93.855	-	23,306.00	23,306.00
	Obesity, Metabolic Syndrome ar				R21AI139829	93.855	-	194,930.00	194,930.00
	Single cell analysis of transp		University of Cincinnat		R21AI142264	93.855	19,998.00	118,850.00	138,848.00
	Targeted manipulation of the [				R21AI142266	93.855	-	10,609.00	10,609.00
	Therapeutic target discovery				R21AI142704	93.855	-	119,624.00	119,624.00
	Copper tolerance and homeosta		University of Cincinnat		R21AI143467	93.855	55,366.00	58,117.00	113,483.00
	Genetics of organ-specific lup		University of Cincinnat		R21AI145304	93.855	6,541.00	134,989.00	141,530.00
	Preserving T cell / antigen p				R21AI148612	93.855	-	126,404.00	126,404.00
	Preconceptual paternal enviro				R21AI152100	93.855	-	155,554.00	155,554.00
	Reconstituting the oligogeni		University of Cincinnat		R21AI152575	93.855	4,344.00	204,335.00	208,679.00
	Genetic ancestry differences				R21AI157363	93.855	-	4,050.00	4,050.00
	Volume Expansion in Children v	University of Calgary		1R34AI136783-01A1	R34AI136783	93.855	-	3,182.00	3,182.00
	Comparison of high dose flu va	Vanderbilt University Medical Cente		VUMC83193	R34AI150532	93.855	-	39,270.00	39,270.00
	A Nanoparticle-Based Multival		Virginia Tech		R56AI148426	93.855	19,427.00	126,114.00	145,541.00
	An experimentally-refined, dy				R56AI153442	93.855	-	242,935.00	242,935.00
	Pathogenesis and therapeutic targeting				T32AI118697	93.855	-	124,925.00	124,925.00
	Gene therapy for SCID-X1 with	Children's Hospital Bostor		GENFD0001865408	U01AI125051	93.855	-	2,187.00	2,187.00
	Gene Regulation as a Foundation for Aut		Stanford University.		U01AI130830	93.855	19,680.00	520,324.00	765,479.00
			The Scripps Research Institute				51,749.00	-	
			University of Colorado				157,364.00	0.00	
			University of Nebraska Medical Cente				16,362.00	-	
	COVID-19 Exosomes and the Immune Respo	Stanford University		62502353-128779	COVID-19 U01AI135950-03S1	93.855	-	3,961.00	3,961.00
	Impact of the Initial Influenz		Emory University		U01AI144673	93.855	756,709.00	3,471,577.00	4,939,271.00
			Fundacion para la salud y la Educacio				108,720.00	-	
			University of Cincinnat				602,265.00	-	
	COVID-19 Epidemiology and Immu		University of Cincinnat		COVID-19 U01AI144673-02S1	93.855	56,250.00	1,286,163.00	1,342,413.00
	Dynamic regulatory network mo	Icahn School of Medicine at Mount Sina		0255-E053-4609	U01AI150748	93.855	-	430,670.00	430,670.00
	Atopic dermatitis: mechanisms				U01AI152034	93.855	-	149,806.00	149,806.00
	Multi-omics of the Frequent E:				U01AI159087	93.855	-	21,626.00	21,626.00
	Epithelial Genes in Allergic Inflammatio				U19AI070235	93.855	-	1,413,091.00	1,413,091.00
	COVID-19 Epithelial Genes in Allergic				COVID-19 U19AI070235-14S1	93.855	-	12,359.00	12,359.00
	COVID-19 Epithelial Genes in Allergic				COVID-19 U19AI070235-15S1	93.855	-	398,660.00	398,660.00
	Airway inflammation and airway monit	University of California San Dieg	University of Cincinnati.	U19AI070535	U19AI070535	93.855	9,977.00	39,522.00	49,499.00
	Consortium of Eosinophilic Gastro		Ann & Robert H Lurie Children's Hospita		U54AI117804	93.855	10,461.00	480,804.00	1,058,796.00
			Arkansas Children's Hospita				23,407.00	-	
			Baylor College of Medicine				20,031.00	-	
			Children's Hospital of Philadelphia				80,405.00	-	
			Mount Sinai School of Medicine				12,886.00	-	
			Northwestern University				96,928.00	-	
			University of California				13,520.00	-	
			University of Colorado				161,615.00	-	
			University of Illinois at Chicago				91.00	-	
			University of North Carolina-Chapel Hi				81,892.00	-	
			University of Pennsylvania				41,385.00	-	
			University of Utah				6,857.00	-	
			Vanderbilt University Medical Cente				23,935.00	-	
			Wake Forest Univ School of Medicine				4,579.00	-	
	COVID-19 HEROs-Consortium of Eosinophilic		University of Colorado		COVID-19 U54AI117804-06S1	93.855	42,979.00	171,829.00	214,808.00
	Extension of clinical data st				UH2AI145837	93.855	-	215,396.00	215,396.00
	International Maternal Pediat	Johns Hopkins School of Medicine		PTCL02	UM1AI068632	93.855	-	3,881.00	3,881.00
	Pre-SUNBEAM Skin Tape Transcr	Benaroya Research Institute at Virginia Maso		FY20ITN385	UM1AI109565	93.855	-	18,929.00	18,929.00
	Inner City Asthma Consortium :	University of Wisconsin-Madisor		UM1AI114271	UM1AI114271	93.855	-	705,880.00	705,880.00
	COVID-19 Inner City Asthma Consortium S	University of Wisconsin-Madison		0000000639	COVID-19 UM1AI114271-06S1	93.855	-	80,825.00	80,825.00
	Vaccine and Treatment Evalua		Nationwide Childrens Hospita		UM1AI148372	93.855	15,587.00	699,237.00	714,824.00
	COVID-19 Vaccine and Treatment Evalua				COVID-19 UM1AI148372-01S1	93.855	-	2,659,907.00	2,659,907.00
	COVID-19 Vaccine and Treatment Evalua				COVID-19 UM1AI148372-02S1	93.855	-	37,644.00	37,644.00
	Leadership Group for an Infec	Emory University		UM1AI148684	UM1AI148684	93.855	-	59,981.00	59,981.00
	New Horizons In The Preventio	Johns Hopkins University	University of Cincinnat	2004813187	UM2AI130836	93.855	43,018.00	337,210.00	380,228.00
	CISA Clinical Vaccine Safety Evaluatior		University of Cincinnat		200-2012-53661	93.RD	69,098.00	436,082.00	505,180.00
	Human Adenovirus Infection and Di:	Children's Hospital of Philadelphia		HHSN272201600014C	HHSN272201600014C	93.RD	-	87,423.00	87,423.00
	Nitazoxanide in Acute and Chronic Nor	Northwestern University Medical Schoc		SP0033779 60044358	HHSN272201600016C	93.RD	-	168,444.00	168,444.00
	Vaccine and Treatment Eval Units (VTEU				HHSN27220130001 6I	93.RD	-	1,653,599.00	1,653,599.00
					Allergy, Immunology and Transplantation Research Total		**3,158,411.00**	**25,598,400.00**	**28,756,811.00**
Arthritis, Musculoskeletal and Skin Diseases Researc	Elucidating the mechanisms o				F32AR077396	93.846	-	28,341.00	28,341.00
	Monocyte and macrophage polarizatic				K08AR072075	93.846	-	157,289.00	157,289.00
	Behavioral Interventions and Long Term				K24AR056687	93.846	-	5,882.00	5,882.00
	Cincinnati Rheumatic Diseases Re:		Brigham and Women's Hospita		P30AR070549	93.846	11,129.00	739,391.00	750,520.00
	Pediatric musculOskeletal anc				P30AR076316	93.846	-	432,410.00	432,410.00
	Neuromuscular Intervention Targete	Mayo Clinic		CHI-263812-01	R01AR055563	93.846	-	61,754.00	61,754.00
	Deciphering mechanisms of myot				R01AR068286	93.846	-	425,886.00	425,886.00
	Multi-site Randomized Clinical Trial of FI		Children's Hospital Bostor		R01AR070474	93.846	97,886.00	810,450.00	1,397,313.00
			Children's Mercy Hospita				129,249.00	-	
			Connecticut Childrens Medical Cente				123,463.00	-	
			Emory University				17,744.00	-	
			Indiana University				124,620.00	-	
			Nationwide Childrens Hospita				79,491.00	-	
			Ohio State University				14,410.00	-	
	In vivo role of the fibroblast in muscula				R01AR071301	93.846	-	357,125.00	357,125.00
	Transcription Factor Genetics				R01AR073228	93.846	-	455,093.00	455,093.00
	Complement in Human Lupus: De	Nationwide Children's Hospita		700165-0519-00	R01AR073311	93.846	-	11,010.00	11,010.00
	GSK3 beta study in patients w				R01AR073379	93.846	-	252,612.00	252,612.00
	Identifying neural pathophysi		Universitat De Barcelona		R01AR074795	93.846	42,775.00	286,270.00	329,045.00
	Epigenetic Determinants Influe		Children's Hospital of Philadelphia		R01AR075857	93.846	7,771.00	438,625.00	502,940.00
			Duke University				12,923.00	-	
			Johns Hopkins University				6,573.00	-	
			Stanford University				37,048.00	-	
	Neuroplastic Mechanisms for th		University of Cincinnat		R01AR076153	93.846	9,156.00	121,687.00	130,843.00
	Improving Pediatric Lupus Nepl				R34AR071651	93.846	-	62,681.00	62,681.00
	Improving delivery of therape				R61AR076771	93.846	-	358,444.00	358,444.00
	Electrical Coupling of Circula		Salk Institute		R61AR078060	93.846	9,835.00	127,136.00	136,971.00
	Real-Time Sensorimotor Feedbac		University of Cincinnati.		U01AR067997	93.846	43,022.00	186,684.00	231,157.00
			University of North Carolina-Chapel Hi				1,451.00	-	
	The Child-Centered Outcomes in Prac	Children's Hospital of Philadelphia		3210940919-XX	U19AR069525	93.846	-	135.00	135.00
	PEARL: Pathway Exploration anc	Feinstein Institute for Medical Researcl		UH2AR067688 Hildemar	UH2AR067688	93.846	-	14,323.00	14,323.00
					Arthritis, Musculoskeletal and Skin Diseases Research Tota		**768,546.00**	**5,333,228.00**	**6,101,774.00**
Assistance Programs for Chronic Disease Prevention and Contr	SEARCH for Diabetes in Youth Registry				U18DP006134	93.945	-	180,756.00	180,756.00
					Assistance Programs for Chronic Disease Prevention and Control Tota		**-**	**180,756.00**	**180,756.00**
Biomedical Research and Research Trainin	Mouse and Guinea Pig Models for Cyt		Pennington Biomedical Research Cente		HHSN27200003	93.859	112,609.00	720,147.00	832,756.00
	The Role of Olfactomedin 4 in Septic				K08GM124298	93.859	-	152,761.00	152,761.00
	Mechanisms governing context-				R00GM111825	93.859	-	228,592.00	228,592.00
	Role of Vpu, Tetherin, and Sig		University of Wisconsin Systen		R01AI150475	93.859	30,830.00	251,077.00	281,907.00
	Biochemical and Computational Analysi				R01GM055479	93.859	-	467,999.00	467,999.00
	Mechanisms of Homeodomain Tra		University of Cincinnat		R01GM079428	93.859	50,752.00	226,644.00	277,396.00
	Studies of Metal-Dependent Intercellula		University of Colorado		R01GM094363	93.859	29,780.00	322,063.00	351,843.00
	DNA Damage Response Pathways				R01GM098605	93.859	-	191,736.00	191,736.00
	DNA Damage Response Pathways	University of California-Davis		A21-2844-S001	R01GM098605	93.859	-	7,046.00	7,046.00
	Molecular and Neural Mechanisr				R01GM107582	93.859	-	263,575.00	263,575.00
	Novel diagnostic and stratification tools				R01GM108025	93.859	-	156.00	156.00

	G-CSF in Human Severe Congenita				R01GM110628	93.859	-	33.00	33.00
	Viral and Cellular Determinan				R01GM111027	93.859	-	2,308.00	2,308.00
	Regulatory Mechanisms Governing				R01GM111987	93.859	-	1,842.00	1,842.00
	Age-Depenedent Mechansims of M				R01GM115973	93.859	-	393,301.00	393,301.00
	Endocytic Trafficking and Cell Signaling	The University of Texas Southwester		0001239	R01GM120196	93.859	-	132,979.00	132,979.00
	Epigenetic Regulation of Gene Expres				R01GM122776	93.859	-	124,613.00	124,613.00
	Epigenetic Regulation of Gene Expres	University of California-Davis		A21-3093-S001	R01GM122776	93.859	-	12,319.00	12,319.00
	Elucidating the Mechanism of Precisio				R01GM122956	93.859	-	271,146.00	271,146.00
	Role of STAT3 in sepsis-induced ad				R01GM126551	93.859	-	277,349.00	277,349.00
	Applying common variant gene	Vanderbilt University Medical Cente		VUMC 77403	R01GM130791	93.859	-	43,344.00	43,344.00
	Functional characterization o		Ohio State University		R01GM134731	93.859	39,336.00	304,707.00	344,043.00
	Death-Seq, a Method for Genom				R21GM135634	93.859	-	126,776.00	126,776.00
	A Synthetic Approach for Bacte	University of Cincinnat		013094-002	R21GM137321	93.859	-	11,865.00	11,865.00
	Growing Community Change Rese	University of Cincinnat		011577-004	R25GM129234	93.859	-	11,858.00	11,858.00
	WE ENGAGE via Data and Stories t		Miami University		R25GM129808	93.859	48,278.00	149,953.00	205,867.00
			University of Cincinnat				7,636.00	-	
	Macrophage regulation of the sperr				R35GM119458	93.859	-	319,400.00	319,400.00
	Sepsis from Bedside to Bench to Bedsid		Children's Hospital Med Center of Akro		R35GM126943	93.859	1,500.00	494,525.00	518,947.00
			Children's Hospital Oaklan				1,500.00	-	
			Childrens Hospital of Orange Count				500.00	-	
			Children's Hospital of Philadelphi				5,000.00	-	
			Indiana Universit				6,500.00	-	
			Stanford Universit				500.00	-	
			University of Florid				2,500.00	-	
			Vanderbilt University Medical Cente				6,422.00	-	
	Molecular Analysis of primar				R35GM131875	93.859	-	324,520.00	324,520.00
	Host Response to Trauma Resea	University of Cincinnat		1016094	T32GM847828	93.859	-	54,219.00	54,219.00
					Biomedical Research and Research Training Tota		**343,643.00**	**5,888,853.00**	**6,232,496.00**
Blood Diseases and Resources Researcl	Sickle Cell Anemia, Splenic P				K23HL153763	93.839	-	156,512.00	156,512.00
	The racial disparity in plate				R00HL136784	93.839	-	236,211.00	236,211.00
	Role of FA Proteins in Hematopoiesi				R01HL076712	93.839	-	265,394.00	265,394.00
	Mechanisms of granulocyte hom		Imperial College of Science Technolog		R01HL122661	93.839	1,617.00	463,213.00	464,830.00
	Chronic thrombus ablation witl	The University of Chicag		FP066598-A	R01HL133334	93.839	-	45,166.00	45,166.00
	Cellular crosstalk in hematopoietic micr		University of Michigar		R01HL136529	93.839	5,889.00	312,443.00	318,332.00
	Normal and Pathological Hematopoieti				R01HL141418	93.839	-	381,448.00	381,448.00
	Small molecules targeting Rho/				R01HL147536	93.839	-	688,516.00	688,516.00
	The roles of mDia2 in hematop	Northwestern University Medical Schoc		60055894 CCH	R01HL148012	93.839	-	80,213.00	80,213.00
	Linking Endotypes and Outcome	Children's Hospital of Philadelphi		3201710624	R01HL148054	93.839	-	62,380.00	62,380.00
	MIDAS: Microangiopathy, Endotl	The Ohio State University Research Fn		60078812	R01HL148247	93.839	-	82,042.00	82,042.00
	The role of mitochondria in h				R01HL151654	93.839	-	143,297.00	143,297.00
	The Role of Erythroblastic Is		The Feinstein Institute Medical Researcl		R01HL152099	93.839	200,131.00	429,945.00	630,076.00
	Defining human hematopoietic				R21HL150678	93.839	-	94,524.00	94,524.00
	Decoding innate immune signaling ir				R35HL135787	93.839	-	863,691.00	863,691.00
	Improving outcomes in CF pati	Dartmouth College		R1069	R56HL139846	93.839	-	9,502.00	9,502.00
	Cincinnati Cntr of Excellence in Hemoglo				U01HL117709	93.839	-	574.00	574.00
	Realizing Effectiveness Across Continents		Baylor College of Medicine		U01HL133883	93.839	15,512.00	263,122.00	660,707.00
			CEFA/Centre Hospitalier Monkol				68,506.00	-	
			Hospital Pediatrico David Bernardin				105,557.00	-	
			Mbale Regional Referral Hospit				118,977.00	-	
			University of Oxford				44,539.00	-	
			The Feinstein Institute Medical Researcl				25,963.00	-	
			University Health Networl				18,531.00	-	
	Darbepoetin Trial to Improve F	University of Utah		10053175-02	U01HL136318	93.839	-	19,230.00	19,230.00
	Sickle Cell Improvement, Enha	Medical College of Wisconsir		U01HL143477	U01HL143477	93.839	-	6,896.00	6,896.00
					Blood Diseases and Resources Research Tota		**605,222.00**	**4,604,319.00**	**5,209,541.00**
Cancer Biology Researcl	The Role of CHAF1B in Maintair				R00CA230314	93.396	-	250,710.00	250,710.00
	Exploiting proteotoxic stress in therap				R01CA193549	93.396	-	34,122.00	34,122.00
	Hemostatic Factors Drive Prostate Cance				R01CA193678	93.396	-	274,192.00	274,192.00
	A rapid spontaneous murine model c		University of Miam		R01CA196658	93.396	3,537.00	87,384.00	90,921.00
	Coagulation factors modifiers of the color				R01CA204058	93.396	-	261,496.00	261,496.00
	Leukemia stem cell polarity and differe				R01CA204895	93.396	-	454,154.00	454,154.00
	Mechanisms coupling DEK to oncogenesi				R01CA218072	93.396	-	426,609.00	426,609.00
	FA pathway activities in norm				R01CA223790	93.396	-	427,631.00	427,631.00
	The role of transcription elo				R01CA234038	93.396	-	599,020.00	599,020.00
	New activities of the human DE		University of Kentuck		R01CA239605	93.396	17,544.00	415,127.00	432,671.00
	Defining genetic and metaboli	University of Cincinnat		012828-002	R01CA239697	93.396	-	262,366.00	262,366.00
	Patho-Genetic Analysis of Inv		Massachusetts General Hospital		R01CA240317	93.396	66,707.00	340,642.00	713,614.00
			University of Utah				306,265.00	-	
	Modeling myelodysplasi		Johns Hopkins Universit		R01CA253981	93.396	31,261.00	143,525.00	174,786.00
	Infectious pressures on cell c				R21CA257984	93.396	-	9,634.00	9,634.00
	Pathogenic Role of Foxl1 Hep				R37CA225807	93.396	-	341,094.00	341,094.00
	Therapeutic insights through patient				R50CA211404	93.396	-	185,399.00	185,399.00
					Cancer Biology Research Total		**425,314.00**	**4,513,105.00**	**4,938,419.00**
Cancer Cause and Prevention Researc	Addressing ELSI issues in unregulated	University of Louisvill		ULRF16-1486-01	R01CA207538	93.393	-	10,367.00	10,367.00
	Instructive role of MLL fusion protein	The University of Chicag		R01CA215504	R01CA215504	93.393	-	335,754.00	335,754.00
	Research Into Visual Endpoint	Vanderbilt University Medical Cente		VUMV67585	R01CA225005	93.393	-	21,701.00	21,701.00
	Unbiased identification of sp				R01CA226802	93.393	-	446,450.00	446,450.00
	Strenghening epidermal defens				R01CA228113	93.393	-	329,000.00	329,000.00
	Increasing HPV Vaccination Ra				R21CA238170	93.393	-	204,128.00	204,128.00
					Cancer Cause and Prevention Research Tota		**-**	**1,347,400.00**	**1,347,400.00**
Cancer Detection and Diagnosis Researcl	Integrated Informatic and Exp	University of Pennsylvani		577035	R01CA227485	93.394	-	433,545.00	433,545.00
	Detection and characterizatio		University of Cincinnat		R21CA240664	93.394	71,314.00	103,793.00	175,107.00
	Redefining hemophagocytic lym				R21CA256390	93.394	-	90,916.00	90,916.00
					Cancer Detection and Diagnosis Research Tota		**71,314.00**	**628,254.00**	**699,568.00**
Cancer Research Manpower Tota	Patient Preferences and Adherence i		Seattle Children's Hospita		K07CA200668	93.398	4,745.00	134,065.00	138,810.00
	Targeting MBNL1-mediated alte				K08CA237753	93.398	-	34,672.00	34,672.00
	Pathways to Cancer Therapeutic	University of Cincinnat		1016448	T32CA117846	93.398	-	158,926.00	158,926.00
	Post-Graduate Hematology/Oncolog	University of Cincinnat		1016321	T32CA236764	93.398	-	58,018.00	58,018.00
					Cancer Research Manpower Total		**4,745.00**	**385,681.00**	**390,426.00**
Cancer Treatment Researcl	Transporters and hematopoietic toxicit	St Jude's Children's Hospita		R01CA194206	R01CA194206	93.395	-	30,319.00	30,319.00
	Linked regulation of tumor angiogenesi				R01CA207068	93.395	-	346,413.00	346,413.00
	Mechanism of non-oncogene addictio				R01CA211594	93.395	-	494,013.00	494,013.00
	Targeting TET1 signaling to treat acut	City of Hope		R01CA211614	R01CA211614	93.395	-	65,937.00	65,937.00
	Innovative Pain and Symptom M	University of Californi		2018-3581	R01CA222012	93.395	-	14,524.00	14,524.00
	(PQ10) Role of Gut Microbiot	The University of Texas Southwester		R01CA231303	R01CA231303	93.395	-	200,501.00	200,501.00
	Targeted Inhibition in Leuker				R01CA237016	93.395	-	364,403.00	364,403.00
	Co-targeting S6 and TAM kina	University of Cincinnat		12653-002	R01CA239657	93.395	-	16,827.00	16,827.00
	Mechanism of Therapy in high-				R01CA250516	93.395	-	555,280.00	555,280.00
	Targeted Inhibition in Tripl				R21CA229930	93.395	-	182,993.00	182,993.00
	COG NCTN Network Group Operat	Children's Hospital of Philadelphi		2U10CA180886	U10CA180886	93.395	-	193,771.00	193,771.00
	Childhood Cancer Survivor Stud	St Jude's Children's Hospita		U24CA055727	U24CA055727	93.395	-	150,138.00	150,138.00
	The Pediatric Brain Tumor Cons	St Jude's Children's Hospita		110068210-7947557	UM1CA081457	93.395	-	74,437.00	74,437.00
					Cancer Treatment Research Total		**-**	**2,689,556.00**	**2,689,556.00**
Cardiovascular Diseases Researcl	Cardiovascular Impact of Gata4 Loss				F30HL137239	93.837	-	3,317.00	3,317.00
	Nr2f1a suppresses bulbous arte				F31HL147399	93.837	-	34,344.00	34,344.00
	Prox1 and oscillatory shear s				F31HL150935	93.837	-	28,188.00	28,188.00
	Nr2fla promotes atrial mainte				F31HL152600	93.837	-	40,627.00	40,627.00
	Defining the role of DHHC3 i				F32HL154387	93.837	-	57,291.00	57,291.00
	The Role of PPARa in Cardiac Dysfunctio				K08HL133377	93.837	-	158,271.00	158,271.00

	A genetic and molecular approa				K08HL143177	93.837	-	154,476.00	154,476.00
	Therapeutic Response Evaluation and A				K23HL128885	93.837	-	177,868.00	177,868.00
	Uncovering compensatory mecha				R00HL135258	93.837	-	137,506.00	137,506.00
	Dissecting the role of novel				R00HL141630	93.837	-	341,313.00	341,313.00
	Molecular pathways controlling				R01HL060562	93.837	-	403,237.00	403,237.00
	Thrombospondin 4 regulates ad				R01HL105924	93.837	-	436,537.00	436,537.00
	Venous Malformations (VM): A M				R01HL117952	93.837	-	95,375.00	95,375.00
	Targeted, Highly Sensitive, N				R01HL119747	93.837	-	11,648.00	11,648.00
	Childhood CV Risk and Adult CVD Ou		Universit of Turku		R01HL121230	93.837	27,324.00	827.00	138,760.00
			University of Iowa				8,316.00	0	
			University of Minnesota				102,293.00	-	
	Functional Impact of Col18a1/Endostatin	Johns Hopkins School of Medicine		JHU;R01HL132153	R01HL132153	93.837	-	37,101.00	37,101.00
	Hippo Signaling in Heart Developmer				R01HL132211	93.837	-	276,907.00	276,907.00
	Unraveling ancestry and environment		University of Cincinnat		R01HL132344	93.837	25,561.00	294,514.00	320,075.00
	Paracrine hypothesis underlying cardiac	Temple University School of Medicine		R01HL132391	R01HL132391	93.837	-	60,251.00	60,251.00
	Molecular examination of mitochondri		University of California		R01HL132831	93.837	1,357.00	164,117.00	165,474.00
	Targeting pathologic G-protein signalin				R01HL133695	93.837	-	462,799.00	462,799.00
	Role of Collagen COL22A1 in intracrai		Indiana University		R01HL134815	93.837	720.00	63,145.00	63,865.00
	Clinical and mechanistic role	Johns Hopkins School of Medicine		R01HL135114	R01HL135114	93.837	-	64,689.00	64,689.00
	Regulatory mechanisms of adult cardi				R01HL135848	93.837	-	339,464.00	339,464.00
	Autologous Cardiomyocytes from Mas	University of Cincinnat		UC;R01HL136025	R01HL136025	93.837	-	10,074.00	10,074.00
	Molecular mechanisms of atrial develo				R01HL137766	93.837	-	300,610.00	300,610.00
	Circadian Rhythms and Interna	University of Massachusetts, Amhers		19-010568 A00	R01HL138551	93.837	-	320,582.00	320,582.00
	Retinoic acid-dependent epigenetic anc				R01HL141186	93.837	-	356,789.00	356,789.00
	Cela1 in Lung Development and Diseas				R01HL141229	93.837	-	555,082.00	555,082.00
	Familial hypercholesterolemi	Columbia University Medical Cente		7(GG012850-01)	R01HL141823	93.837	-	20,769.00	20,769.00
	Predictive Molecular Markers				R01HL142210	93.837	-	414,109.00	414,109.00
	Cardiac fibroblasts in postna				R01HL142217	93.837	-	530,120.00	530,120.00
	Mechanisms of Congenital Heart Valv				R01HL143881	93.837	-	382,876.00	382,876.00
	HDL compostion/function and ca	University of Washingtor		UWSC10977	R01HL144558	93.837	-	39,033.00	39,033.00
	Molecular mechanisms underlyi				R01HL144774	93.837	-	503,951.00	503,951.00
	Characterizing the formation	University of Texas Southwesterr		R01HL144793	R01HL144793	93.837	-	27,677.00	27,677.00
	MRI Phenotyping of Early BPD		University of Wisconsin Systerr		R01HL146689	93.837	144,111.00	556,966.00	701,077.00
	Impact of Well-Timed vs. Mis-				R01HL147915	93.837	-	319,980.00	319,980.00
	Novel Methods to Grow the Imp				R01HL147957	93.837	-	560,321.00	560,321.00
	Ultrasound-Mediated Controlle	University of Cincinnat		012268-003	R01HL148451	93.837	-	68,915.00	68,915.00
	Accelerating research to advai		Brigham and Women's Hospita		R01HL151604	93.837	8,808.00	146,345.00	489,181.00
			Children's Hospital Bostor				230,338.00	-	
			Vanderbilt University Medical Cente				103,690.00	-	
	Endothelial subpopulations i				R01HL156270	93.837	-	125,256.00	125,256.00
	Lipoprotein Interactions in tl				R01HL157260	93.837	-	47,664.00	47,664.00
	National Biological Sample and Dat				R24HL105333	93.837	-	4,728.00	4,728.00
	Pediatric REPLAcement of the F	Children's Hospital of Philadelphia		3201202621	R34HL142142	93.837	-	15,523.00	15,523.00
	Effect of dietary approaches	Johns Hopkins School of Medicine		R56HL139620	R56HL139620	93.837	-	29,511.00	29,511.00
	Understanding Cardiovascular Disease				T32HL125204	93.837	-	301,920.00	301,920.00
	Cincinnati Children's Summer Med Student				T35HL113229	93.837	-	20,251.00	20,251.00
	Administrative Coordinating C		Children's Hospital Bostor		U01HL131003	93.837	113,092.00	4,353,986.00	5,687,255.00
			Children's Hospital of Philadelphia				120,949.00	-	
			Columbia University				96,635.00	-	
			Harvard College				242,618.00	-	
			J David Gladstone Institutes				72,634.00	-	
			Mount Sinai School of Medicine				33,794.00	-	
			The Feinstein Institute Medical Researcl				22,491.00	-	
			University of California				345,236.00	-	
			University of Utah				259,191.00	-	
			Yale University				26,629.00	-	
	Multicenter Interventional Lymphangi	University of Cincinnat		U01HL131755	U01HL131755	93.837	-	78,148.00	78,148.00
	Lung Map submission with UC Sa	University of California San Dieg		125063615	U01HL148867	93.837	-	48,053.00	48,053.00
	Role of Epithelial YAP in Alve	University of Maryland (Baltimore		1701192	U24HL134763	93.837	-	5,477.00	5,477.00
	Data Coordinating Center for PHN	New England Research Institutes	University of Cincinnat	U24HL135691	U24HL135691	93.837	30,863.00	243,702.00	274,565.00
	A cloud-based decision suppor	Cleveland Clin Lerner Col of Med of CWRU	University of Cincinnat	1232-Sub	U54HL119810	93.837	3,448.00	31,474.00	34,922.00
	Pediatric Heart Network Prairieland Con		Indiana University		UG1HL135678	93.837	179,402.00	220,213.00	399,615.00
					Cardiovascular Diseases Research Total		**2,199,500.00**	**14,483,917.00**	**16,683,417.00**
Child Health and Human Development Extramural Researc	Child Health Research Career Develo				K12HD028827	93.865	-	463,891.00	463,891.00
	Surviving and Thriving in the				K23HD094855	93.865	-	178,334.00	178,334.00
	Electrophysiological Biomarke				K23HD101416	93.865	-	127,776.00	127,776.00
	Developmental Mechanisms of Trache		Columbia University		P01HD093363	93.865	310,311.00	1,034,137.00	1,354,448.00
			University of Central Missour				10,000.00	-	
	Pediatric HIV/AIDS Cohort Stuc	Harvard Medical Schoc		117267-0184-5119274	P01HD103133	93.865	-	9,548.00	9,548.00
	Xenbase: The Xenopus model organisr		University of Calgary		P41HD064556	93.865	849,647.00	623,504.00	1,473,151.00
	HEAL Initiative: Antenatal Op	RTI Internationa		5-312-0217179-65988L	PL1HD101059	93.865	-	270,805.00	270,805.00
	Prenatal Genetic Diagnosis by	Columbia University Medical Cente		1(GG014633-01)	R01HD055651	93.865	-	4,771.00	4,771.00
	Molecular signaling in uterine receptivit				R01HD068524	93.865	-	279,301.00	279,301.00
	Impact of Emergency Departmen		Children's National Medical Cente		R01HD071915	93.865	1,589.00	152,025.00	196,081.00
			University of Michigar				2,107.00	-	
			Washington University				40,360.00	-	
	Long-Term Outcomes of Interver	Oklahoma State University		1-571918-CHMC	R01HD074579	93.865	-	9,954.00	9,954.00
	A Cognitive Test Battery for	University of California-Davis		1580GYB180	R01HD076189	93.865	-	93,619.00	93,619.00
	Bone Mineral Accretion in Young Childre		Children's Hospital of Philadelphia		R01HD076321	93.865	55,817.00	97,050.00	152,867.00
	Roles of STAT5b in IGF-1 Production and				R01HD078592	93.865	-	954.00	954.00
	An Intervention to Reduce SHS Exposure		San Diego State University		R01HD083354	93.865	1,195.00	66,896.00	75,528.00
			University of Arizona				7,437.00	-	
	Improving ADHD Teen Driving by Targeting Vi		Saint Louis University		R01HD084430	93.865	8,652.00	370,770.00	416,069.00
			University of Massachusetts Bostor				18,444.00	-	
			University of North Carolina-Chapel Hi				18,203.00	-	
	The role of executive functions in reading		Kennedy Krieger Institute, Inc		R01HD086011	93.865	46,802.00	262,096.00	534,034.00
			Technion Research & Development Fo				200,387.00	0.00	
			Washington University				24,749.00	-	
	Decision-Making for Patients Born with di	University of Michigar		R01HD086583	R01HD086583	93.865	-	56,429.00	56,429.00
	PED Screen: Pediatric Sepsis EHR Regis	Northwestern University Medical Schoc		R01HD087363	R01HD087363	93.865	-	73,911.00	73,911.00
	Pharmacogenetics of Oxycodone	Indiana University Healtl		R01HD089458	R01HD089458	93.865	-	39,110.00	39,110.00
	Identifying Pharmacogenomic Predictors		CARRA Inc		R01HD089928	93.865	51,260.00	337,824.00	508,556.00
			Children's Mercy Hospita				24,946.00	-	
			Duke University				71,444.00	-	
			Wake Forest University				23,082.00	-	
	FA DDR Pathway in Germline Integrit				R01HD089932	93.865	-	148,430.00	148,430.00
	The Effect of Emergency Depar	Medical College of Wisconsir		R01HD091302-03	R01HD091302	93.865	-	49,240.00	49,240.00
	Development and Testing of a I	Nationwide Children's Hospita		700171-0719-00	R01HD091347	93.865	-	11,735.00	11,735.00
	Harnessing "omics": A Systems Biology		Institute for Systems Biology		R01HD091527	93.865	8,418.00	13,314.00	21,732.00
	Vocational Fit Assessment anc	Colorado State University		R01HD092474	R01HD092474	93.865	-	73,241.00	73,241.00
	Exploration of the genetic ba		Baylor College of Medicine		R01HD092989	93.865	19,133.00	31,773.00	50,906.00
	Disorders/Differences of Sex Develo	University of Michigar		SUBK00008039	R01HD093450	93.865	-	12,024.00	12,024.00
	CES1 Genetic Variation Influer	University of Florida		SUB00001726	R01HD093612	93.865	-	70,323.00	70,323.00
	A multicenter collaborative	Children's National Medical Cente		30004927-01	R01HD093622	93.865	-	63,320.00	63,320.00
	Early Childhood Communicatio	University of California-Davis		A19-0460-S002	R01HD093654	93.865	-	110,128.00	110,128.00
	High-Intensity Interval Train	University of Cincinnat		011445-02	R01HD093694	93.865	-	4,311.00	4,311.00
	Cognitive Outcome Measures i		Colorado State University		R01HD093754	93.865	185,192.00	348,308.00	533,500.00
	Thrombotic microangiopathy (TM		Children's Hospital Los Angeles		R01HD093773	93.865	98,352.00	736,081.00	883,703.00
			The Hospital for Sick Childrer				18,177.00	-	
			University of Cincinnat				31,093.00	-	
	Improving the Detection of ST	Children's National Medical Cente		30004942-05	R01HD094213	93.865	-	99,028.00	99,028.00
	Exploring vascular-mesenchyma				R01HD094698	93.865	-	261,549.00	261,549.00
	Dosing and Pilot Efficacy of		Connecticut Childrens Medical Cente		R01HD094862	93.865	86,550.00	267,063.00	353,613.00
			University of Cincinnat		R01HD094862	93.865	40,406.00	-	40,406.00
	Stress Hydrocortisone In Pedia	Children's Hospital Bostor		GENFD0001858329	R01HD096901	93.865	-	228,580.00	228,580.00

	Deciphering the pathophysiolo				R01HD098280	93.865	-	469,793.00	469,793.00
	Discovery of Molecular Target:	UCLA School of Public Health		R01HD098389	R01HD098389	93.865	-	100,662.00	100,662.00
	Executive Function Outcome Me:	Colorado State University		R01HD099150-01	R01HD099150	93.865	-	144,055.00	144,055.00
	Improving the Effectiveness ar		University of Cincinnat		R01HD099775	93.865	154,734.00	162,066.00	316,800.00
	Genomics of bone and body com	Children's Hospital of Philadelphia		GRT-00000601	R01HD100406	93.865	-	27,257.00	27,257.00
	Enhancing Nursing Care Reliab	Ohio State University		60077379	R01HD100455	93.865	-	43,624.00	43,624.00
	Skeletal Health and Bone Marr	Children's Hospital Bostor		GENFD0001843699	R01HD101421	93.865	-	330,692.00	330,692.00
	Integrating genomic studies o				R01HD101669	93.865	-	22,279.00	22,279.00
	Endocannabinoid Signaling dur				R01HD103475	93.865	-	226,831.00	226,831.00
	Automated Risk Assessment fo				R01HD103630	93.865	-	51,364.00	51,364.00
	Endotypes in Children with Se	University of Michigar		SUBK00010627	R01HL149910	93.865	-	29,711.00	29,711.00
	Headaches and Migraines: Pube	University of Cincinnat		011742-002	R03HD094236	93.865	-	369.00	369.00
	Role of Cholesterol Biosynthe:		University of Cincinnat		R03HD094882	93.865	60,984.00	49,788.00	110,772.00
	The effects of Methylphenidate		University of Cincinnat		R03HD097689	93.865	28,718.00	52,814.00	81,532.00
	Novel eMedicine Self-Managemen				R21HD087844	93.865	-	50,358.00	50,358.00
	Deletion of CRH Expression in Rhesus				R21HD090196	93.865	-	1,582.00	1,582.00
	Teaching Academic Success Skills tc				R21HD090334	93.865	-	15,527.00	15,527.00
	Novel therapeutic target for intrauterin				R21HD090856	93.865	-	130.00	130.00
	ADAMTS6 in Craniofacial and Skeleta				R21HD091263	93.865	-	80,397.00	80,397.00
	PCSK9 and Pediatric Sepsis-Re				R21HD092896	93.865	-	106,521.00	106,521.00
	Mechanism-targeted treatment :		Dartmouth College		R21HD093033	93.865	2,637.00	46,992.00	49,629.00
	Early Prediction of Cognitve D				R21HD094085	93.865	-	27,386.00	27,386.00
	Human-animal interaction to p		Miami University		R21HD095132	93.865	7,001.00	78,666.00	85,667.00
	Neonatal PBPK-PD Modeling of M				R21HD095418	93.865	-	13,293.00	13,293.00
	Driving Skills of Adolescents				R21HD096014	93.865	-	162,728.00	162,728.00
	Prediction of Fetal Maturity a		American Academy of Pediatrics		R21HD096256	93.865	37,718.00	163,832.00	201,550.00
	Pluripotent Stem Cell-derived live				R21HD098417	93.865	-	180,100.00	180,100.00
	Brain organoid modeling of Ga				R21HD102788	93.865	-	170,597.00	170,597.00
	Pediatric Injury: Modules to Manag	University of Utah		1046978	R24HD096350	93.865	-	235,362.00	235,362.00
	Evaluating Assessment and Mec		Univ of Calif.-Davis-Mmrrc		R61HD100934	93.865	242,832.00	252,484.00	495,316.00
	Enhancing Pediatric Treatment Adhe				T32HD068223	93.865	-	242,663.00	242,663.00
	Cincinnati Pediatric Clinical Pharma				T32HD069054	93.865	-	37,156.00	37,156.00
	Translational medicine and me		University of California		U54HD104461	93.865	206,148.00	399,404.00	859,506.00
			University of Cincinnat				128,327.00	-	
			University of Oklahoma Health Science				14,606.00	-	
			University of Texas Southwestern				111,021.00	-	
	NICHD Cooperative Multicenter Neonata				UG1HD027853	93.865	-	312,061.00	312,061.00
						Child Health and Human Development Extramural Research Tota	**3,248,479.00**	**11,369,697.00**	**14,618,176.00**
Developmental Disabilities Basic Support and Advocacy Gran	Healthy Lifestyles for People with Disab	Ohio Dev Disabilities Counci	University of Illinois at Chicago	17CH03FA21	21010HSCDD	93.630	16,500.00	72,057.00	88,557.00
						Developmental Disabilities Basic Support and Advocacy Grants Tota	**16,500.00**	**72,057.00**	**88,557.00**
Diabetes, Digestive, and Kidney Diseases Extramural Researc	Identification of the geneti				F30DK123841	93.847	-	36,231.00	36,231.00
	Development and Disease of th				F31DK118823	93.847	-	36,548.00	36,548.00
	The role of retinoic acid sigr				F31DK120164	93.847	-	2,329.00	2,329.00
	Defining the Basis of Epithelial Defects				K01DK109081	93.847	-	136,305.00	136,305.00
	The Role of DDX41 in Inheritec				K01DK121733	93.847	-	161,616.00	161,616.00
	Glucocorticoid and circadian c				K01DK121875	93.847	-	157,589.00	157,589.00
	Predicting Severity and Impro				K23DK118190	93.847	-	173,376.00	173,376.00
	Digestive Health Center: Bench to Bedside				P30DK078392	93.847	-	1,145,479.00	1,145,479.00
	Personalized Cystic Fibrosis T		University of Cincinnat		P30DK117467	93.847	3,524.00	1,084,610.00	1,088,134.00
	Critical Translational Studies in Pediatric				P50DK096418	93.847	-	797,835.00	797,835.00
	Immunologic Dysfunction in Bi				R01DK064008	93.847	-	434,593.00	434,593.00
	Self-Management of Type 1 Diabete				R01DK069486	93.847	-	475.00	475.00
	Adolescent Bariatric Surgery		Sanford Research North		R01DK080020	93.847	49,571.00	599,714.00	675,523.00
			The CDM Group, Inc				26,238.00	-	
	Inhibition of an Apical cAMP/c		St Jude Children's Research Hospita		R01DK080834	93.847	18,454.00	255,810.00	274,264.00
	The role of Hedgehog Signaling	University of Arizona		567639	R01DK083402	93.847	-	23,097.00	23,097.00
	Biological Basis of Phenotype:				R01DK083781	93.847	-	540,507.00	540,507.00
	Genetic basis of virus inducec		University of Cincinnat		R01DK091566	93.847	8,550.00	390,762.00	399,312.00
	LPA2 receptor-containing complexes i				R01DK093045	93.847	-	60,302.00	60,302.00
	Control of hepatic T cell resp				R01DK095001	93.847	-	517,097.00	517,097.00
	Immunopathogenesis of non-alc				R01DK099222	93.847	-	671,334.00	671,334.00
	Outcome of NASH in Adolescents after				R01DK100429	93.847	-	217,093.00	217,093.00
	Cdc42, hematopoietic stem cell polarit				R01DK104814	93.847	-	10,801.00	10,801.00
	The Mechanism Regulating Renal Pro				R01DK106225	93.847	-	336,509.00	336,509.00
	Mechanisms of genetic risk at 2p23 ir				R01DK107502	93.847	-	325,454.00	325,454.00
	Role of Hepatic RNA Silencing in Insulin				R01DK107530	93.847	-	308,863.00	308,863.00
	Mechanistic and therapeutic rc	University of California-Davis		R01DK107541	R01DK107541	93.847	-	12,280.00	12,280.00
	Building a functional biliary system from		University of California		R01DK107553	93.847	224,240.00	135,315.00	359,555.00
	Nonlinear Ultrasound: an Imaging Bior	University of Michigar		3004067897	R01DK109032	93.847	-	13,318.00	13,318.00
	Level and timing of diabetic hypergl		MedStar Health Research Institute, In		R01DK109956	93.847	3,167.00	624,954.00	631,857.00
			Tufts Medical Center, Inc				3,736.00	-	
	Fibrin(ogen) control of metab	University of North Carolina		5116413	R01DK112778	93.847	-	21,886.00	21,886.00
	Targeting IRAK1/4 in Myelodysplasti				R01DK113639	93.847	-	389,908.00	389,908.00
	Epigenomic control of antimicrobia		University of Cincinnat		R01DK114123	93.847	5,432.00	301,938.00	307,370.00
	Host integration of commensa				R01DK116868	93.847	-	507,831.00	507,831.00
	Roles of circadian rhythms ir	University of Cincinnat		011798-002	R01DK117005	93.847	-	12,968.00	12,968.00
	Type 2 cytokines and innate I				R01DK117119	93.847	-	504,788.00	504,788.00
	Molecular targets in cholesta:				R01DK117266	93.847	-	364,698.00	364,698.00
	Manipulating DNA Damage-respor				R01DK117632	93.847	-	462,695.00	462,695.00
	Surgical or Medical Treatmen		University of Colorado		R01DK119450	93.847	270,876.00	288,066.00	558,942.00
	The role of SPRY2 in the color	Children's Hospital Los Angeles		RGF011923-A	R01DK119694	93.847	-	49,862.00	49,862.00
	Molecular regulation of hepa				R01DK120765	93.847	-	308,397.00	308,397.00
	Hox Genes and Lineage Infide				R01DK120842	93.847	-	450,130.00	450,130.00
	Retinoic acid gene regulator				R01DK120847	93.847	-	369,118.00	369,118.00
	Regulation of functionally di:				R01DK121062	93.847	-	777,511.00	777,511.00
	Diabetes Journey: From system:		University of Florida		R01DK121295	93.847	210,825.00	234,720.00	445,545.00
	Molecular mechanisms for bon	Northwestern University Medical Schoc		60052734 CCHMC	R01DK121354	93.847	-	22,940.00	22,940.00
	Sox Proteins Modulate Genomi				R01DK123092	93.847	-	247,839.00	247,839.00
	Role of extracellular vesicl		Vanderbilt University		R01DK123181	93.847	30,559.00	476,511.00	507,070.00
	Regulation of Niche Cell Diffe				R01DK123299	93.847	-	116,457.00	116,457.00
	Mitochondria mediated interce				R01DK124115	93.847	-	267,830.00	267,830.00
	Microbiota-mediated fibrotic	University of North Carolina		5117429	R01DK124617	93.847	-	11,940.00	11,940.00
	Host and viral determinants o	Children's Hospital of Philadelphia		R01DK125418	R01DK125418	93.847	-	251,149.00	251,149.00
	Gene regulatory networks in tl				R01DK125577	93.847	-	369,479.00	369,479.00
	Limited Competition for the C	Wake Forest University Health Science:		241-100710-553791	R01DK127208	93.847	-	106,805.00	106,805.00
	Pharmacokinetic Evaluation t				R03DK118314	93.847	-	82,795.00	82,795.00
	Durability of Epethelial Defe				R03DK124751	93.847	-	73,218.00	73,218.00
	Early MRI Prediction of Respor				R21DK114657	93.847	-	123,359.00	123,359.00
	Epigenetic and functional dete				R21DK123691	93.847	-	171,286.00	171,286.00
	Enhancing effectiveness of ex		Spectrum Health Hospitals		R34DK118510	93.847	5,818.00	69,974.00	78,540.00
			University of Minnesota				2,748.00	-	
	A generalizable framework fo		University of Pittsburgh		RC2DK122376	93.847	104,190.00	352,890.00	500,182.00
			Yale University				43,102.00	-	
	Systems Biology of Bone Marrov	Children's Hospital Bostor		GENFD0001876495	RC2DK122533	93.847	-	18,829.00	18,829.00
	Research Training in Pediatric				T32DK007695	93.847	-	180,856.00	180,856.00
	Pediatric Gastroenterology an				T32DK007727	93.847	-	425,470.00	425,470.00
	Research Training in Child Bel				T32DK063929	93.847	-	266,467.00	266,467.00
	TODAY2 Phase 2 (T2P2): Long-Term	George Washington University		2U01DK061230-13	U01DK061230	93.847	-	35,012.00	35,012.00
	Non Alcoholic Steatohepatiti:	Cleveland Clin Lerner Col of Med of CWRU		1324-SUB	U01DK061732	93.847	-	174,195.00	174,195.00
	Colorado Center of Childhood I	University of Colorado		FY21.220.003	U01DK062453	93.847	-	47,053.00	47,053.00
	Clinical Center for Cholestat				U01DK062497	93.847	-	801,225.00	801,225.00
	CKID IV (patient care and sal:	Children's Mercy Hospita		18-0007	U01DK066143	93.847	-	64,223.00	64,223.00
	Defining the intestinal stem c		Baylor College of Medicine		U01DK103117	93.847	95,828.00	365,558.00	461,386.00
	Modeling diabetes using an in		Cleveland State Universit		UG3DK119982	93.847	85,616.00	-	106,772.00

			University of Illinois at Chicag				21,156.00	-	
	Modeling diabetes using an in		Cleveland State Universit		UH3DK119982	93.847	164,366.00	877,519.00	1,281,246.00
			University of Illinois at Chicag				239,361.00	-	
	Teen Longitudinal Assess of Bariatric	University of Colorado		FY 18.896.002	UM1DK072493	93.847	-	253,406.00	253,406.00
	Teen Longitudinal Assess of Bariatric	University of Cincinnat		UM1DK095710	UM1DK095710	93.847	-	517,858.00	517,858.00
						Diabetes, Digestive, and Kidney Diseases Extramural Research Tota	**1,617,357.00**	**21,026,855.00**	**22,644,212.00**
Disabilities Preventior	Improving the Health of Ohioar	Ohio State University		60071385	NU27DD000015-04-00	93.184	-	41,190.00	41,190.00
						Disabilities Prevention Total	**-**	**41,190.00**	**41,190.00**
Discovery and Applied Research for Technological Innovations to Improv	MRI Compatible Robot for Impro	Children's National Medical Cente		30004680-03	R01EB025179	93.286	-	136,358.00	136,358.00
	MRI and Deep Learning for Ear				R01EB029944	93.286	-	300,561.00	300,561.00
	Quantification of Liver Fibros				R01EB030582	93.286	-	39,814.00	39,814.00
	Development Of Hybrid Trachea	University of Cincinnat		011164-004	R21EB025378	93.286	-	14,027.00	14,027.00
	Center for Point-of-Care Techr	Johns Hopkins University		U54EB007958	U54EB007958	93.286	-	191,590.00	191,590.00
						Discovery and Applied Research for Technological Innovations to Improve Human Health Tota	**-**	**682,350.00**	**682,350.00**
Drug Abuse and Addiction Research Program	Using Administrative and Clinica				K01DA041620	93.279	-	160,470.00	160,470.00
	Reducing Secondhand Smoke exp	University of Cincinnat		011088-002	K01DA044313	93.279	-	6,644.00	6,644.00
	Endocannabinoid Signaling during		Indiana University		R01DA006668	93.279	23,056.00	237,947.00	261,003.00
	Cooperative Mechanisms of HIV	Univ of Texas Medical Branch-Galvesto		20-84853-01	R01DA050530	93.279	-	36,715.00	36,715.00
	Role of Siglec-1 in HIV Intera		University of Cincinnat		R01DA051895	93.279	10,964.00	407,229.00	418,193.00
	4/5 HEAL Consortium: Establish		University of Cincinnati.		R34DA050268	93.279	28,918.00	248,168.00	277,086.00
	Omics analysis of HIV during s	University of Cincinnat		012074-003	R61DA048439	93.279	-	16,372.00	16,372.00
	First-In-Human Study of a Huma	University of Cincinnat		012264-003	U01DA048525	93.279	-	58,295.00	58,295.00
	Ohio Valley Node-Network	University of Cincinnat		009942-043	UG1DA013732	93.279	-	38,467.00	38,467.00
						Drug Abuse and Addiction Research Programs Tota	**62,938.00**	**1,210,307.00**	**1,273,245.00**
Emergency Medical Services for Childre	Pediatric Emergency Care App		Medical College of Wisconsir		U03MC22684	93.127	165,853.00	316,473.00	562,871.00
			Washington University				80,545.00		
						Emergency Medical Services for Children Total	**246,398.00**	**316,473.00**	**562,871.00**
Environmental Healtt	Genomics and geospatial analy	University of Cincinnat		011429-063	P30ES006096	93.113	-	39,431.00	39,431.00
	Early life perfluoroalkyl sub:	Brown University		00001249	R01ES025214	93.113	-	142,196.00	142,196.00
	Developmental Effects of Mang:	University of Kentucky		3200002784-20-083	R01ES026446	93.113	-	118,278.00	118,278.00
	Prenatal Exposure to Endocrin	Pennsylvania State Universit		S000447-NIH	R01ES026903	93.113	-	94,074.00	94,074.00
	Internalizing Behaviors and Neur		University of Cincinnat		R01ES027224	93.113	26,507.00	494,612.00	542,092.00
			University of Pennsylvani:				20,973.00	-	
	Contribution of Thirdhand Smoke		San Diego St. University		R01ES027815	93.113	238,189.00	238,264.00	499,721.00
			University of Cincinnat				23,268.00	0.00	
	Developmental neurotoxicity c	University of Cincinnat		011150-006	R01ES028277	93.113	-	212,838.00	212,838.00
	Longitudinal Study of Endocrir	University of Cincinnat		011720-002	R01ES029133	93.113	-	56,298.00	56,298.00
	Investigating the Impact of Pl	Johns Hopkins University		2004295370	R01ES030078	93.113	-	89,627.00	89,627.00
	Effects of DDE exposure on ad	University of Southern Californi:		129965417	R01ES030364	93.113	-	10,010.00	10,010.00
	ADVOCATE: Prevalence and Clin		San Diego St. Univ. Research Foundatio		R01ES030743	93.113	33,713.00	422,366.00	478,465.00
			University of Cincinnat				22,386.00	-	
	Epigenetics, Air Pollution, ar	University of Cincinnat		013074-002	R01ES031054	93.113	-	155,249.00	155,249.00
	Longitudinal Impact of Air Po				R01ES031621	93.113	-	159,041.00	159,041.00
	Gene-pesticide interactions ar				R01ES032270	93.113	-	309,891.00	309,891.00
	Histone Lysine Crotonylation in Pater				R21ES027117	93.113	-	148.00	148.00
	Developing and Evaluating Nov		University of Kentucky		R21ES030092	93.113	14,615.00	104,686.00	119,301.00
	Innovative Personal Monitorin	RTI Internationa		c1-340-0217531-66041L	R21ES030142	93.113	-	80,216.00	80,216.00
	Assessing Personal Exposure to Ultr:				R33ES024713	93.113	-	163,148.00	163,148.00
	Validation of Cross-Species B	Litron Laboratorie:		R44ES028163	R44ES028163	93.113	-	3,372.00	3,372.00
	Environmental Carcinogenesis :	University of Cincinnat		1016232	T32ES007250	93.113	-	107,124.00	107,124.00
	Molecular Epidemiology in Children's	University of Cincinnat		1016305	T32ES010957	93.113	-	169,847.00	169,847.00
	Mammary Carcinogenesis: puberta	Michigan State University		U01ES026119	U01ES026119	93.113	-	65,854.00	65,854.00
	Prenatal inflammatory exposure		Univeristy of Californi:		U01ES029234	93.113	268,905.00	426,922.00	695,827.00
						Environmental Health Total	**648,556.00**	**3,663,492.00**	**4,312,048.00**
Extramural Research Programs in the Neurosciences and Neurological D	Machine Learning Approach to				F31NS115447	93.853	-	27,363.00	27,363.00
	The Role of Raptor in Tempora				F31NS115525	93.853	-	33,497.00	33,497.00
	Mitogenic Activities in Neurofibromat				R01NS028440	93.853	-	430,862.00	430,862.00
	Comparison of Hemorrhagic anc	University of Cincinnat		012830-004	R01NS030678	93.853	-	277,100.00	277,100.00
	Roles of Gsx factors in telencephalic				R01NS044080	93.853	-	861.00	861.00
	Study of Activity-Dependent Sympatheti	University of Cincinnat		010133-007	R01NS045594	93.853	-	6,140.00	6,140.00
	Molecular, cellular and physiologica		University of Florid:		R01NS054794	93.853	93,231.00	895,374.00	988,605.00
	mTOR regulation of aberrant neuron:		Washington University		R01NS062806	93.853	26,225.00	183,969.00	210,194.00
	Identification and reversal o				R01NS065020	93.853	-	388,035.00	388,035.00
	Molecular control of neurogenesis in the				R01NS069893	93.853	-	12,167.00	12,167.00
	Brain Mechanisms Supporting Individua				R01NS085391	93.853	-	135,793.00	135,793.00
	Signaling pathways regulating olig				R01NS088529	93.853	-	107,192.00	107,192.00
	MicroRNA-mediated silencing of Kv4.2				R01NS092705	93.853	-	185,139.00	185,139.00
	A New Model to Identify Preterm Neonate				R01NS094200	93.853	-	241,410.00	241,410.00
	Early Prediction of Cerebral Palsy in Pr				R01NS096037	93.853	-	292,023.00	292,023.00
	Genetic and environmental influences or		Phoenix Children's Hospita		R01NS096053	93.853	3,438.00	383,596.00	464,250.00
			University of Alabama at Birminghar				2,340.00	-	
			University of Cape Towr				10,589.00	-	
			University of Exete				6,187.00	-	
			University of Pittsburgh				57,495.00	-	
			University of Tennessee				605.00	-	
	GABAergic Sensorimotor Dysfunction	Kennedy Krieger Research Institut		113091-0321	R01NS096207	93.853	-	115,051.00	115,051.00
	miR-155 and RUNX function in neurc				R01NS097233	93.853	-	379,942.00	379,942.00
	Binding of Epstein Barr Virus EBNA2		Stanford University		R01NS099068	93.853	13,409.00	210,972.00	224,381.00
	Biguanide Sensitivity of Glioma Sterr		University of Cincinnat		R01NS099162	93.853	7,239.00	249,632.00	256,871.00
	ICH Recovery Gran	University of Cincinnat		011078-014	R01NS100417	93.853	-	20,479.00	20,479.00
	Prevention of Cerebrospinal (C	Children's Hospital Los Angele:		000013147-C	R01NS101029	93.853	-	33,782.00	33,782.00
	Distinct Mechanisms of Cognitive				R01NS101321	93.853	-	534,843.00	534,843.00
	Assessing Population-based Rac	University of Cincinnat		011815-003	R01NS103824	93.853	-	59,407.00	59,407.00
	Progranulin:A Novel Gene in Gaucher	New York University		17-A0-00-008041-01	R01NS103931	93.853	-	159,749.00	159,749.00
	A novel smart patch for the	University of Cincinnat		012058-002	R01NS103992	93.853	-	204,086.00	204,086.00
	Sensitization of developing s				R01NS105715	93.853	-	360,853.00	360,853.00
	Targeting the Hippo signaling	University of Cincinnat		011818-002	R01NS105787	93.853	-	3,935.00	3,935.00
	Targeting the Hippo signaling	University of Houstor		R200017	R01NS105787	93.853	-	105,508.00	105,508.00
	Mechanisms linking hemostati				R01NS107258	93.853	-	437,110.00	437,110.00
	Functional analysis of the mi				R01NS107453	93.853	-	410,385.00	410,385.00
	Creatine Transporter Deficienc	University of Virginia		GB10578.160162	R01NS108763	93.853	-	37,797.00	37,797.00
	Headache Assessment of Childre	Columbia University		10(GG015970-01)	R01NS110826	93.853	-	12,249.00	12,249.00
	Spinal circuitry for ventilat				R01NS112255	93.853	-	297,986.00	297,986.00
	Mechanisms of muscle afferen				R01NS113965	93.853	-	161,314.00	161,314.00
	Bystander gene deletions in c		University of Cincinnat		R01NS114074	93.853	12,637.00	454,994.00	467,631.00
	CNS in congenital DM1: pathoge				R01NS115662	93.853	-	335,856.00	335,856.00
	Diagnostic validity and safet	Johns Hopkins University		R01NS115929	R01NS115929	93.853	-	122,575.00	122,575.00
	Circuit defects underlying ir	Univ of California Los Angele:		1580 G YB180	R01NS117597	93.853	-	242,263.00	242,263.00
	A Novel Role for Phospholamba	University of Daytor		RSC19036	R03NS109836	93.853	-	2,213.00	2,213.00
	Functional Genomics of Mamma	SRI Internationa		1515488	R21NS101983	93.853	-	167.00	167.00
	Neuromagnetic High Frequency C				R21NS104459	93.853	-	93,721.00	93,721.00
	Using a ketogenic diet to tre:				R21NS111217	93.853	-	209,949.00	209,949.00
	MEG Connectivity-Based Mappin		The Hospital for Sick Childrer		R21NS106631	93.853	6,029.00	15,067.00	34,018.00
			University of Cincinnat				12,922.00	0	
	HIV-1 Particle Capture and VCC				R21NS107031	93.853	-	21,337.00	21,337.00
	Exploring the molecular mechar				R21NS112890	93.853	-	210,441.00	210,441.00
	Targeting complement 5a-medi:				R33NS112407	93.853	-	16,996.00	16,996.00
	Ras Proteins in Nerve Tumorig				R37NS083580	93.853	-	314,544.00	314,544.00
	Molecular and signaling mechanisms				R37NS096359	93.853	-	50,212.00	50,212.00
	Manipulation of microRNA for C				R56NS114124	93.853	-	270,073.00	270,073.00

	Targeting complement 5a-media				R61NS112407	93.853	-	186,341.00	186,341.00
	SPRINT: Signature for Pain Rec	Stanford University Medical Cente		R61NS114926	R61NS114926	93.853	-	417,860.00	417,860.00
	APRISE-Dementia (Assessing Pop	University of Cincinnat		1 RF1 NS117643-01	RF1NS117643	93.853	-	24,014.00	24,014.00
	Cerebrovascular Fellowship Tr	University of Cincinnat		013104-002	T32NS047996	93.853	-	11,030.00	11,030.00
	Early biomarkers of Autism Spectrum	Children's Hospital Bostor		GENFD0001563311	U01NS082320	93.853	-	7,579.00	7,579.00
	Preventing Epilepsy Using Vigabatrin	University of Alabama-Birminghan		000510297-001	U01NS092595	93.853	-	61,703.00	61,703.00
	High-dose Erythropoietin for Asphyxi	University of Californi		10018sc	U01NS092764	93.853	-	26,349.00	26,349.00
	Cincinnati Neuroscience Clinic	University of Cincinnat		011609-006	U24NS107200	93.853	-	151,127.00	151,127.00
	Developmental Synaptopathies	Children's Hospital Bostor		GENFD0001761815	U54NS092090	93.853	-	87,940.00	87,940.00
				Extramural Research Programs in the Neurosciences and Neurological Disorders Total			**252,346.00**	**10,729,952.00**	**10,982,298.00**
Food and Drug Administration_Research	IND:138100. A phase I and surg				R01FD006352	93.103	-	1,609.00	1,609.00
	Quercetin Chemoprevention for				R01FD006353	93.103	-	189,957.00	189,957.00
	Effectiveness of Alternative A	Children's Hospital of Philadelphia		Grant ID GRT-00000248	U01FD006292	93.103	-	24,598.00	24,598.00
	Development of the Full Qualif	Temple University School of Medicine		266646-CHMC	U01FD006978	93.103	-	34,133.00	34,133.00
	I-ACT for Children, Global Pediatric Clin	Inst For Adv Clin Trials For Children		CCHMC-01	U18FD006297	93.103	-	57,686.00	57,686.00
					Food and Drug Administration_Research Total		**-**	**307,983.00**	**307,983.00**
Grants for Training in Primary Care Medicine and Dentistry	Dental Faculty Loan Repayment Prog				D87HP31252	93.884	-	112,786.00	112,786.00
				Grants for Training in Primary Care Medicine and Dentistry Total			**-**	**112,786.00**	**112,786.00**
Lung Diseases Research	Identifying Gli-Regulated Targ				F30HL142201	93.838	-	594.00	594.00
	The role of the long non-coding RNA Fal				K08HL130666	93.838	-	43,309.00	43,309.00
	Mechanistic evaluation of a no				K08HL140178	93.838	-	164,847.00	164,847.00
	Personalized Model Systems to				K08HL144825	93.838	-	125,318.00	125,318.00
	TGF-Beta Regulates CFTR-Mediat				K08HL151762	93.838	-	64,671.00	64,671.00
	Using technology-assisted step				K23HL139992	93.838	-	130,103.00	130,103.00
	Early detection of regional BO				R00HL138255	93.838	-	247,423.00	247,423.00
	Pathogenesis-Based Diagnostics				R01HL085453	93.838	-	348,825.00	348,825.00
	Pulmonary Macrophage Transplan		University of Washington		R01HL118342	93.838	174,001.00	318,830.00	492,831.00
	Mechanisms of IL-17A-mediated enhance				R01HL122300	93.838	-	872.00	872.00
	UTE MRI to monitor CF lung disease		Politecnico di Milano-Dipartimento		R01HL131012	93.838	20,000.00	799,146.00	819,146.00
	Interstitial resident fibroblasts direct				R01HL131661	93.838	-	177,350.00	177,350.00
	WT1 Regulation of Pulmonary Fibrosis		University of Cincinnati		R01HL134801	93.838	11,226.00	412,540.00	456,559.00
			University of Michigan				32,793.00	-	
	Pulmonary Epithelial Dynamics	University of Cincinnati		011283-002	R01HL135122	93.838	-	18,679.00	18,679.00
	Genome edited iPS cell-derived macro				R01HL136721	93.838	-	158,013.00	158,013.00
	Role of EMC3/TMEM111 in Alveolar				R01HL136722	93.838	-	364,744.00	364,744.00
	Transcriptional Regulation of Endo				R01HL141174	93.838	-	510,875.00	510,875.00
	R01- Mapping environmental con		Erasmus MC		R01HL141286	93.838	41,783.00	368,605.00	410,388.00
	Mechanisms controlling early h	Children's Hospital Los Angeles		P2018-0376B	R01HL141856	93.838	-	7,102.00	7,102.00
		The Lundquist Institute		CCHMC/032223-01	R01HL141856	93.838	-	20,561.00	20,561.00
	Development of neonatal innate				R01HL142708	93.838	-	485,380.00	485,380.00
	Validating Quantitative Magnet		University of Cincinnati		R01HL143011	93.838	5,262.00	577,415.00	582,677.00
	The role of sex in the life cy	University of Cincinnati		012029-002	R01HL146266	93.838	-	57,820.00	57,820.00
	Investigating the Mechanisms o		University of Cincinnati		R01HL147351	93.838	16,670.00	202,904.00	279,358.00
			University of Tennessee				59,784.00	-	
	Bedside Exclusion of Pulmonary	Indiana University		8492-CHMC	R01HL148247	93.838	-	15,226.00	15,226.00
	Perinatal Dysbiosis, Lung Deve		National Jewish Med & Res Cen		R01HL149366	93.838	2,745.00	306,612.00	309,357.00
	Molecular Mechanisms Regulated		University of Cincinnati		R01HL149631	93.838	31,321.00	564,659.00	595,980.00
	Role of IGF Axis in Pulmonary	Johns Hopkins School of Medicine		2004833966	R01HL150070	93.838	-	84,785.00	84,785.00
	Imaging and Molecular Phenotyp				R01HL151588	93.838	-	129,994.00	129,994.00
	A Role for EYA3 In Vascular Re				R01HL152094	93.838	-	444,619.00	444,619.00
	Development of novel therapeut				R01HL152973	93.838	-	75,676.00	75,676.00
	Uterine signaling networks in		University of Cincinnati		R01HL153045	93.838	182,012.00	338,814.00	520,826.00
	Tissue niches for ILC3 develop				R01HL155611	93.838	-	133,124.00	133,124.00
	Epigenetic Regulation of the M				R01HL156860	93.838	-	25,155.00	25,155.00
	Role of IGF in pulmonary arter	Johns Hopkins School of Medicine		2004234609	R21HL145422	93.838	-	79,967.00	79,967.00
	RhoA in T Cell-mediated Airway				R56HL141499	93.838	-	9,960.00	9,960.00
	Commercial Translation of Biom				R61HL154105	93.838	-	246,650.00	246,650.00
	Human gene transfer and macrop				R61HL156888	93.838	-	27,344.00	27,344.00
	Pulmonary Development and Dise				T32HL007752	93.838	-	284,057.00	284,057.00
	Cincinnati Children's Summer M				T35HL113229	93.838	-	19,860.00	19,860.00
	ORBEX: Primary Prevention of Asthma	University of Arizona		PO 438886	U01HL130045	93.838	-	199,184.00	199,184.00
	Editing Alveolar Progenitor Cells for		Battelle Memorial Institute		U01HL134745	93.838	35,864.00	396,774.00	1,134,380.00
			Boston University				372,817.00	-	
			Johns Hopkins University				16,812.00	-	
			National Jewish Med & Res Cen				11,359.00	-	
			University of Pennsylvania				266,809.00	-	
			Washington University				33,945.00	-	
	Preparing for a hybrid trial o	Children's Hospital of Philadelphia		3201160620	U01HL143475	93.838	-	1,365.00	1,365.00
	LungMap Phase II - Building a		Cedars-Sinai Medical Center		U01HL148856	93.838	13,018.00	801,538.00	878,265.00
			Massachusetts General Hospital				7,557.00	-	
			The Broad Institute Inc.				56,152.00	-	
	The LungMAP Data Coordination		Research Triangle Institute		U24HL148865	93.838	39,400.00	638,925.00	740,587.00
			The Broad Institute Inc.				61,110.00	0	
			University of California				1,152.00	-	
	Hydrocortisone for BPD Respiratory	Children's Hospital of Philadelphia		3200930818	UH3HL137872	93.838	-	38,131.00	38,131.00
					Lung Diseases Research Total		**1,493,592.00**	**10,468,345.00**	**11,961,937.00**
Maternal and Child Health Federal Consolidated Programs	Region V East Comprehensive Care	Hemophilia Foundation of Michigan		H30MC24047	H30MC24047	93.110	-	$ 21,234.00	21,234.00

	Leadership Education in Neurodev	University of Cincinnati		T73MC0003225	T73MC0003225	93.110	-	$ 651,473.00	651,473.00
	ODH Health Resources and Srv Admin	Ohio State University	University Hospitals of Cleveland	60076721	U7AMC337160101	93.110	48,712.00	$ 122,059.00	170,771.00
	Autism Intervention Research Network	Massachusetts General Hospital		UA3MC11054	UA3MC11054	93.110	-	$ 56,645.00	56,645.00
	DBPNet ADHD Node	Children's Hospital of Philadelphia		3208960819-S1	UA3MC20218	93.110	-	$ 52,584.00	52,584.00
						Maternal and Child Health Federal Consolidated Programs Total	**48,712.00**	**903,995.00**	**952,707.00**
Medical Library Assistance	Improving Intensive Care Medication				R01LM012230	93.879	-	224.00	224.00
	Personal Health Record for Youth				R01LM012816	93.879	-	359,776.00	359,776.00
	A Framework for Automated and				R01LM013222	93.879	-	200,150.00	200,150.00
						Medical Library Assistance Total	**-**	**560,150.00**	**560,150.00**
	Contributions of the striatal				F30MH123056	93.242	-	33,657.00	33,657.00
	A Multi-Method Investigation to Dist				K23MH108603	93.242	-	54,841.00	54,841.00
	Anomalous Sensorimotor Physiology				K23MH112936	93.242	-	199,422.00	199,422.00
	A Family Navigator Interventio				K23MH125138	93.242	-	109,201.00	109,201.00
	Molecular Mechanisms Controlli		University of Cincinnati		R01MH090740	93.242	52,234.00	566,162.00	618,396.00
	1/2 Anomalous Motor System Phy				R01MH095014	93.242	-	315,938.00	315,938.00
	4/7-Collaborative genomic stud				R01MH115962	93.242	-	92,535.00	92,535.00
	Nationwide dissemination of a		American Academy of Pediatrics		R01MH118488	93.242	41,461.00	457,220.00	498,681.00
	Patient and Provider perspecti	University of North Carolina		5113985	R01MH118955	93.242	-	44,802.00	44,802.00
	Longitudinal Examination of Sl				R01MH122415	93.242	-	157,129.00	157,129.00
	Molecular Dissection of Synapt	University of Massachusetts, Amherst		21-015624 A00	R01MH122519	93.242	-	8,165.00	8,165.00
	Neuron- and microglia-specific	University of Cincinnati		012928-002	R01MH123545	93.242	-	53,262.00	53,262.00
	Parsing Neurobiological Bases		Purdue University		R01MH123831	93.242	9,576.00	279,007.00	306,984.00
			University of Cincinnati				18,401.00	-	
	Neuroinflammation, asthma and	University of Cincinnati		012047-002	R21MH117483	93.242	-	38,582.00	38,582.00
	Improving Medication Continuity				R34MH112648	93.242	-	229,388.00	229,388.00
	Emotion coaching skills as an		University of California		R34MH115897	93.242	33,539.00	156,492.00	236,414.00
			University of Georgia				46,383.00	-	
	Improving Adherence in Adolesc	Case Western University		R34 MH117206-01A1	R34MH117206	93.242	-	20,661.00	20,661.00
	Validation of a salivary miRNA	Quadrant Biosciences		1293481860000	R42MH111347	93.242	-	36,431.00	36,431.00
Mental Health Research Grants	(ED-STARS) Emergency Dept Screen	University of Michigan		3003298263	U01MH104311	93.242	-	342.00	342.00
						Mental Health Research Grants Total	**201,594.00**	**2,853,237.00**	**3,054,831.00**
National Bioterrorism Hospital Preparedness Program	Eastern Great Lakes Pediatric	University Hospital of Cleveland		U3REP190615	U3REP190615	93.889	-	58,810.00	58,810.00
						National Bioterrorism Hospital Preparedness Program Total	**-**	**58,810.00**	**58,810.00**
National Center on Sleep Disorders Research	Circadian Clock Dysregulation				K08HL148551	93.233	-	140,842.00	140,842.00
	Improving Outcomes in Pediatri				K99HL144822	93.233	-	146,797.00	146,797.00
	Sleep Restriction and the Adolescent				R01HL120879	93.233	-	739.00	739.00
	Positive airway pressure for t	Children's Hospital of Philadelphia		3201930820	R61HL151253	93.233	-	160,575.00	160,575.00
						National Center on Sleep Disorders Research Total	**-**	**448,953.00**	**448,953.00**
National Research Service Award in Primary Care Medicine	National Research Service Award				T32HP10027	93.186	-	398,475.00	398,475.00
						National Research Service Award in Primary Care Medicine Total	**-**	**398,475.00**	**398,475.00**
Nursing Research	Influence of Parent-Nurse Comm				K23NR017396	93.361	-	148,395.00	148,395.00
	A Clinic-Based Interdisciplinary Inter		Univ of Oklahoma Health Sciences		R01NR014248	93.361	42,639.00	150,158.00	192,797.00
	Self-Management in Adolescent	Loyola University Chicago		Loyola;R01NR016235	R01NR016235	93.361	-	35,265.00	35,265.00
	Self-Management of Adolescent	Children's Hospital of Philadelphia		3201511123	R01NR017429	93.361	-	109,802.00	109,802.00
	Peer Mentoring to Improve Self	Nationwide Children's Hospital		700160-0219-00	R01NR017533	93.361	-	214,141.00	214,141.00
	Fostering medication adherence		CHOC Children's Hospital		R01NR017794	93.361	92,052.00	348,296.00	645,021.00
			Medical University South Carolina				74,401.00	-	
			North Carolina State University				19,214.00	-	
			Research Inst. at Nationwide Hos				60,968.00	-	
			University of Florida				50,090.00	-	
	Randomized Controlled Trial of		University of Virginia		R01NR019426	93.361	83,975.00	277,802.00	361,777.00
	Identification of causal facto	University of Cincinnati		013249-002	R01NR019531	93.361	-	17,957.00	17,957.00
	Caregiver Self-Management Need	University of Cincinnati		011682-002	R21NR016992	93.361	-	570.00	570.00
	Improving Drug Adherence Using		Nationwide Childrens Hospital		R21NR017633	93.361	13,830.00	50,435.00	76,946.00
			University of Florida				12,681.00	-	
						Nursing Research Total	**449,850.00**	**1,352,821.00**	**1,802,671.00**
Oral Diseases and Disorders Research	Role of the Ciliary Protein C2				F31DE030664	93.121	-	3,960.00	3,960.00
	Prolonger progenitor manintenance				R00DE026239	93.121	-	181,693.00	181,693.00
	Developing Topical Fluoride He	University of Washington		UWSC10797	R01DE026741	93.121	-	60,581.00	60,581.00
	Mandible Development				R01DE027046	93.121	-	619,690.00	619,690.00
	Genetic Analysis of Mammalian				R01DE027091	93.121	-	358,705.00	358,705.00
	Regulation of Craniofacial Dev				R01DE029417	93.121	-	442,640.00	442,640.00
	Function and Regulation of Sem				R21DE030193	93.121	-	41,363.00	41,363.00
	Harnessing the therapeutic potential		The Jackson Laboratory		R35DE027557	93.121	47,094.00	904,762.00	951,856.00
	Velopharyngeal insufficiency f	Phoenix Children's Hospital		SITZMAN-20-03	U01DE029750	93.121	-	131,289.00	131,289.00
	Reduction of bloodstream infec				UG3DE030401	93.121	-	13,771.00	13,771.00
						Oral Diseases and Disorders Research Total	**47,094.00**	**2,758,454.00**	**2,805,548.00**
Poison Center Support and Enhancement Grant Program	Cincinnati Drug and Poison Inf				H4BHS15468	93.253	-	392,221.00	392,221.00
	COVID-19 CARES Funding for Poison Centers				COVID-19 H4CHS37395	93.253	-	88,522.00	88,522.00
						Poison Center Support and Enhancement Grant Program Total	**-**	**480,743.00**	**480,743.00**

Research on Healthcare Costs, Quality and Outcomes	Family-Clinician Partnerships to Improve				K08HS023827	93.226	-	13,007.00	13,007.00
	Predicting Pediatric Readmission:				K08HS024735	93.226	-	145,483.00	145,483.00
	Hospital Management of Acute Resp				K08HS025138	93.226	-	161,763.00	161,763.00
	The Patient and Parent Perspec				K08HS026763	93.226	-	164,556.00	164,556.00
	AHRQ Mentored Clinical Scienti				K08HS026975	93.226	-	191,347.00	191,347.00
	Missed Opportunities for Improving	University of Michigan		3004658567	R01HS024953	93.226	-	11,385.00	11,385.00
	Improving ADHD Behavioral Care Quality				R18HS024690	93.226	-	297,720.00	297,720.00
	Spread of Safety Interventions	Children's Hospital Boston		RHS027401A	R18HS027401	93.226	-	70,061.00	70,061.00
	Pediatric Hospital Care Improv	Kaiser Foundation Research Institute		RNG210310-BUDG01-CC	U18HS025291	93.226	-	5,417.00	5,417.00
						Research on Healthcare Costs, Quality and Outcomes Total	**-**	**1,060,739.00**	**1,060,739.00**
Research Related to Deafness and Communication Disorders	Idiopathic auditory dysfunction in				R01DC014078	93.173	-	218,288.00	218,288.00
	Prevention of Ototoxicity with		Oregon Health & Science University		R01DC017867	93.173	45,338.00	278,978.00	334,615.00
			Washington University				10,299.00	0	
	Pediatric dysphonia: Multidisc	University of South Florida		1219-1068-00-B	R01DC018008	93.173	-	55,311.00	55,311.00
	Technology-assisted language i		University of Colorado		R01DC018550	93.173	60,377.00	418,269.00	478,646.00
	Earliest predictors of languag		University of Cincinnati		R01DC018734	93.173	36,580.00	618,274.00	654,854.00
	A Preliminary Study of the Neu	University of Cincinnati		R15DC017280	R15DC017280	93.173	-	56,179.00	56,179.00
	Multimodal Neuroimaging Distin	University of Cincinnati		R21DC017393	R21DC017393	93.173	-	36,041.00	36,041.00
						Research Related to Deafness and Communication Disorders Total	**152,594.00**	**1,681,340.00**	**1,833,934.00**
Sickle Cell Treatment Demonstration Program	Sickle Treatment and Outcomes Res		Children's Hosp & Clinics of Minnesota		U1EMC27863	93.365	42,406.00	287,890.00	425,059.00
			Indiana Hemophilia & Thrombosis Ctr, Inc				10,333.00		
			Medical College of Wisconsin				38,718.00		
			Sanford Research				23.00		
			Sickle Cell Disease Assoc of America				33,845.00		
			University of Illinois at Chicago				11,844.00		
						Sickle Cell Treatment Demonstration Program Total	**137,169.00**	**287,890.00**	**425,059.00**
Training and Clinical Skills Improvement Projects	Enhanced Surveillance for New Vaccine		University of Cincinnati		U01IP001059	93.185	115,858.00	1,136,115.00	1,251,973.00
	COVID-19 Staat - PREVAIL COVID-19 Suppl		University of Cincinnati	U01IP001059	COVID-19 U01IP001059	93.185	77,707.00	1,084,068.00	1,161,775.00
						Training and Clinical Skills Improvement Projects Total	**193,565.00**	**2,220,183.00**	**2,413,748.00**
Trans-NIH Research Support	Engineering multi-organs in a				DP2DK128799	93.310	-	307,341.00	307,341.00
	Direct Epigenetic Reprogramming of T				DP2GM119134	93.310	-	176.00	176.00
	Decentralized and Reproducible	Duke University		Duke, Brokamp	U2COD023375	93.310	-	104,118.00	104,118.00
	NYU Pediatric Obesity, Metabolism and	NYU Sponsored Programs Administration		UG30D023305	UG3OD023305	93.310	-	41,117.00	41,117.00
	Children's Respiratory Research and	University of Wisconsin-Madison		UG3OD023282	UH3OD023282	93.310	-	1,104,346.00	1,104,346.00
	Developmental Impact of NICU E	Albert Einstein College of Medicine		311397	UH3OD023320	93.310	-	63,008.00	63,008.00
						Trans-NIH Research Support Total	**-**	**1,620,106.00**	**1,620,106.00**
University Centers for Excellence in Developmental Disabilities Educatior	National Training AUCD SCOPE	University of Wyoming		1004506-CHMC	90DDTI0042	93.632	-	101,492.00	101,492.00
	UC University Centers for Excellen	University of Cincinnati		011042-015	90DDUC0013	93.632	-	548,782.00	548,782.00
						University Centers for Excellence in Developmental Disabilities Education, Research, and Service Total	**-**	**650,274.00**	**650,274.00**
Paralysis Resource Center State Pilot Program Total	Ohio SILC UCCEDD Disaster Prep				HHS-2019-ACL-AOD-PRRC-03	93.325	-	16,582.00	16,582.00
						Paralysis Resource Center State Pilot Program Total	**-**	**16,582.00**	**16,582.00**
Vision Research	Regulation of vascular development in		Cleveland Clinic Foundation		R01EY027077	93.867	225,189.00	203,333.00	428,522.00
	Regulation of eye development by	Emory University		T750388	R01EY027711	93.867	-	165,508.00	165,508.00
	Molecular Mechanism of Biallel				R01EY028958	93.867	-	6,395.00	6,395.00
	Gene Therapy of Corneal Dystro	University of Cincinnati		012501-002	R01EY029427	93.867	-	17,440.00	17,440.00
	Predicting uveitis onset in ch		Children's Hospital of Philadelphia		R01EY030521	93.867	280.00	245,278.00	336,115.00
			University of California				164.00	-	
			University of Cincinnati				56,702.00	-	
			Wake Forest Univ School of Medicine				33,691.00	-	
	RNA Nanoparticles for Ocular D	University of Cincinnati		013457-003	R01EY031452	93.867	-	6,258.00	6,258.00
	Light regulated vascular devel				R01EY032029	93.867	-	60,079.00	60,079.00
	Newborn Infant Vision Test	Ohio State University		60078759	R42EY022545	93.867	-	95,803.00	95,803.00
						Vision Research Total	**316,026.00**	**800,094.00**	**1,116,120.00**
Human Genome Researct	Engaging adolescents in deci:				R01HG010166	93.172	-	598,616.00	598,616.00
	Virus-driven human gene misreg		Brigham and Women's Hospital		R01HG010730	93.172	137,050.00	382,245.00	545,139.00
			University of Cincinnati				25,844.00	-	
	Better Outcomes for Children: Promoting				U01HG008666	93.172	-	353,106.00	353,106.00
	Polygenic Risk Scores for Heal				U01HG011172	93.172	-	483,197.00	483,197.00
						Human Genome Research Total	**162,894.00**	**1,817,164.00**	**1,980,058.00**
National Center for Advancing Translational Sciences	Center for Clinical and Transl	University of Cincinnati		KL2TR001426	KL2TR001426	93.350	-	574,069.00	574,069.00
	Disseminating Curative Biological	Children's Hospital Boston		U01TR001814	U01TR001814	93.350	-	124,424.00	124,424.00
	Precision Medicine in the Diag	Tufts Medical Center		5016131-SERV	U01TR002271	93.350	-	81,256.00	81,256.00
	Instrumenting the Delivery Sys	Children's Hospital Boston		GENFD0001706578	U01TR002623	93.350	-	152,954.00	152,954.00
	Data Management and Coordinati		University of Cincinnati		U2CTR002818	93.350	23,426.00	5,794,665.00	5,818,091.00
	Preclinical characterization o		Case Western Reserve University		UG3TR002612	93.350	17,414.00	132,643.00	150,057.00
	Preclinical characterization o				UH3TR002612	93.350	-	232,289.00	232,289.00
	Continuing education for clini	University of Cincinnati		2UL1TR001425	UL1TR001425	93.350	-	2,538,827.00	2,538,827.00
	University of Pittsburgh Clinical	University of Pittsburgh		5UL1TR001857-05	UL1TR001857	93.350	-	41,957.00	41,957.00
						National Center for Advancing Translational Sciences Total	**40,840.00**	**9,673,084.00**	**9,713,924.00**

	Occupational Safety and Health Program	Education and Research Center	University of Cincinnati		010412-094	T42OH008432	93.262	-	13,379.00	13,379.00
						Occupational Safety and Health Program Total		**-**	**13,379.00**	**13,379.00**
	Preventive Health and Health Services Block Grants	Child Injury Grant Program	Stark County (ODH)		07610014IC0220	07610014IC0220	93.991	-	2,720.00	2,720.00
						Occupational Safety and Health Program Total		**-**	**2,720.00**	**2,720.00**
	Research and Training in Complementary and Alternative Medicine	Using fMRI to understand response				K23AT009458	93.213	-	72.00	72.00
		Dissecting Neural Mechanisms S				R01AT010171	93.213	-	658,467.00	658,467.00
		Systems biology of microbe-med	University of Virginia		R01AT010253	R01AT010253	93.213	-	50,817.00	50,817.00
		Mind Body Balance for Pediatı		University of Colorado		U01AT010132	93.213	51,875.00	595,400.00	689,120.00
				University of Virginia				41,845.00		
						Research and Training in Complementary and Alternative Medicine Total		**93,720.00**	**1,304,756.00**	**1,398,476.00**
	Health Program for Toxic Substances and Disease Registry	Pediatric Environmental Health	Univ of Illinois @ Chicago		17852-00	NU61TS000296	93.161	-	47,831.00	47,831.00
						Health Program for Toxic Substances and Disease Registry Total		**-**	**47,831.00**	**47,831.00**
	Healthy Start Initiative	HRSA Cradle Cincinnati		University of Cincinnati		H49MC27823	93.926	116,240.00	1,157,601.00	1,273,841.00
						Healthy Start Initiative Total		**116,240.00**	**1,157,601.00**	**1,273,841.00**
	Affordable Care Act (ACA) Family to Family Health Information Centers	Ohio Family to Family Health I				H84MC28443	93.504	-	102,784.00	102,784.00
						Affordable Care Act (ACA) Family to Family Health Information Centers Total		**-**	**102,784.00**	**102,784.00**
	Rare Disorders: Research, Surveillance, Health Promotion, and Education	Woodward CDC NSBPR Registry 20				U01DD001279	93.315	-	85,181.00	85,181.00
						Rare Disorders: Research, Surveillance, Health Promotion, and Education Total		**-**	**85,181.00**	**85,181.00**
	Blood Disorder Program: Prevention, Surveillance and Research	Community Counts: Public Health Surv	Hemophilia Foundation of Michigan		U27DD001155	U27DD001155	93.080	-	26,126.00	26,126.00
						Blood Disorder Program: Prevention, Surveillance and Research Total		**-**	**26,126.00**	**26,126.00**
	Minority Health and Health Disparities Research	Linking pre- and post-natal psychosocial				R01MD013006	93.307	-	572,413.00	572,413.00
						Minority Health and Health Disparities Research Total		**-**	**572,413.00**	**572,413.00**
	Birth Defects and Developmental Disabilities - Prevention and Surveillance	Beyond EHDI Benchmarks in Earl	University of South Carolina		20-3973	U19DD001218	93.073	-	116,648.00	116,648.00
						Birth Defects and Developmental Disabilities - Prevention and Surveillance Total		**-**	**116,648.00**	**116,648.00**
	Developmental Disabilities Projects of National Significance	Center for Dignity in Healthca		AADMD		90DNHC0001	93.631	86,721.00	178,516.00	478,656.00
				Autistic Self Advocacy Network Inc				25,000.00		
				Family Voices Inc				25,000.00		
				Kennedy Krieger Institute, Inc.				19,988.00		
				Rutgers, The State University				12,466.00		
				University of Kentucky				99,507.00		
				Vanderbilt University Medical Center				31,458.00		
						Developmental Disabilities Projects of National Significance Total		**300,140.00**	**178,516.00**	**478,656.00**
	National Research Service Awards_Health Services Research Training	PEDSnet Application	Children's Hospital of Philadelphia		3201350920	K12HS026393	93.225	-	140,870.00	140,870.00
						National Research Service Awards_Health Services Research Training Total		**-**	**140,870.00**	**140,870.00**
	ACL National Institute on Disability, Independent Living, and Rehabilitatio	Enhancing Parenting Skills: Application	University of Oregon		239530A	90DPHF0003-01-00	93.433	-	83,045.00	83,045.00
		Gaining Real-life skills Over the Web				90IFDV0003-02-00	93.433	-	94,160.00	94,160.00
						ACL National Institute on Disability, Independent Living, and Rehabilitation Research Total		**-**	**177,205.00**	**177,205.00**
	Public Health Emergency Preparedness	Poison Center Bioterrorism Pre	Nationwide Children's Hospital		720441-0620-00	ODH Prime Contract 34225	93.069	-	6,086.00	6,086.00
						Public Health Emergency Preparedness Total		**-**	**6,086.00**	**6,086.00**
	Environmental Public Health and Emergency Response	Asthma In Home	Ohio Department of Health		43960	NUE1EH001385	93.070	-	35,500.00	35,500.00
						Environmental Public Health and Emergency Response Total		**-**	**35,500.00**	**35,500.00**
	Maternal & Child Health Services Block Grants	Asthma in Home	Ohio Department of Health		41534	B04MC325640101	93.994	-	24,900.00	24,900.00
						Maternal and Child Health Services Block Grant to the States Total		**-**	**24,900.00**	**24,900.00**
	Family Smoking Prevention and Tobacco Control Act Regulatory Research	Distinguishing Exposure to Sec	University of Cincinnati		013228-003	R21ES032161	93.077	-	36,738.00	36,738.00
						Family Smoking Prevention and Tobacco Control Act Regulatory Research Total		**-**	**36,738.00**	**36,738.00**
						Dept of Health and Human Serv Total		**17,439,776.00**	**161,570,901.00**	**179,010,677.00**
Dept of Housing and Urban Dev	Healthy Homes Technical Studies Grants	Role of measured and observed	University of Cincinnati		011199	OHHHU0037-17	14.906	-	24,269.00	24,269.00
						Healthy Homes Technical Studies Grants Total		**-**	**24,269.00**	**24,269.00**
	Lead Technical Studies Grants	Analysis of Benefits of Abatem	National Center for Healthy Housing, Inc		MDLTS000818 HUD_NCH	MDLTS0008-18	14.902	-	29,984.00	29,984.00
						Lead Technical Studies Grants Total		**-**	**29,984.00**	**29,984.00**
						Dept of Housing and Urban Dev Total		**-**	**54,253.00**	**54,253.00**
Office of Personnel Management	Intergovernmental Personnel Act (IPA) Mobility Program	IPA Chepelev for Kaufman VA Me				IPA Chepelev	27.011	-	27,015.00	27,015.00
		Role of a common leptin recept				IPA Filippi	27.011	-	5,259.00	5,259.00
		VA IPA - Yongbo Huang				IPA Huang	27.011	-	28,307.00	28,307.00
		Richards VA Merit Kaufman				IPA Richards	27.011	-	54,803.00	54,803.00
		Mechanisms of liver failure				IPA Sharma	27.011	-	70,047.00	70,047.00

		Tripathi VA Merit Kaufman				IPA Tripathi	27.011	-	72,463.00	72,463.00
		Mechanisms of liver failure				IPA Verma	27.011	-	14,838.00	14,838.00
						Intergovernmental Personnel Act (IPA) Mobility Program Total		**-**	**272,732.00**	**272,732.00**
						Office of Personnel Management Total		**-**	**272,732.00**	**272,732.00**
						Research and Development Total		**$ 17,545,822.00**	**$ 166,891,989.00**	**$ 184,437,811.00**
	Medical Assistance Program	Pediatric Behavioral Health In	Ohio State University		60065930	G-2021-05-0069 ODM202014	93.778	-	43,935.00	43,935.00
		Ohio Perinatal Quality Collabo	Ohio State University	Aultman Hospital	60072430	G-2021-05-0069:ODM202004	93.778	971.00	-	35,572.00
				Case Western Reserve University				6,505.00	-	
				Children's Hospital of Akron				2,807.00	-	
				Miami Valley Hospital				13,219.00	-	
				Ohio State University				8,812.00	-	
				University Hospitals of Cleveland				3,258.00	-	
		Ohio Perinatal Quality Collabo	Ohio State University	Case Western Reserve University	60071989	G-2021-05-0069:ODM202010	93.778	3,245.00	-	13,800.00
				Miami Valley Hospital				9,997.00	-	
				University Hospitals of Cleveland				558.00	-	
		Ohio Smoke Free Families Pedia	American Academy of Pediatrics		Carle AAP	G-2021-05-0069	93.778	-	20,400.00	20,400.00
						Medical Assistance Program/Medicaid Cluster Total		**49,372.00**	**64,335.00**	**113,707.00**
	Strengthening Public Health Sys & Svcs thru Natl Partnerships to Improve	Support for Early Childhood St	Assoc of Univ Center on Disabilities		05-21-8815	NU38OT000280-02-02	93.421	-	41,671.00	41,671.00
		COVID-19 - Addressing COVID-19 vaccine ac	Assoc of Univ Center on Disabilities		05-21-8815	NU38OT000280-03-05	93.421	-	4,180.00	4,180.00
		COVID-19-Provider Relief Fund And American Rescue Plan (ARP) Distribution				COVID-19	93.498	-	42,403,258.00	42,403,258.00
Fed Communications Commission		COVID-19 - FCC Cares Act Telehealth Award				COVID-19	32.006	-	715,854.00	715,854.00
		State Opioid Response				MHRSB Hamilton County	93.788	-	153,813.00	153,813.00
		Drug and Poison Control				MHRSB Hamilton County	93.959	-	271,883.00	271,883.00
						Grand Total all Funds		$ 17,595,194.00	$ 210,546,983.00	$ 228,142,177.00

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2021

1. SCOPE OF AUDIT

All federal grant operations of Cincinnati Children's are included in the scope of Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)'s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as Cincinnati Children's cognizant agency for the Single audit.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplemental Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant activity of Cincinnati Children's under programs of the federal government for the year ended June 30, 2021 and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Guidance*. Because the Schedule presents only a selected portion of the operations of Cincinnati Children's, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children's. Cincinnati Children's did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2021.

3. DONATED PERSONAL PROTECTIVE EQUIPMENT (UNAUDITED)

Cincinnati Children's received no donated personal protective equipment from the federal government during the year ended June 30, 2021.

4. PROVIDER RELIEF FUND TAX IDENTIFCATION NUMBER

Cincinnati Children's received COVID-19 Provider Relief funds under the 31-0833936 tax identification number only.

Deloitte.

Deloitte & Touche LLP
50 W 5th Street
Suite 200
Cincinnati, OH 45202-3789
USA

Tel: +513 784 7100
Fax: +513 784 7204
www.deloitte.com

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees of
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated balance sheet as of June 30, 2021, and the related consolidated statements of operations and changes in net assets and of cash flows for the year then ended, and the related notes to the consolidated financial statements which collectively comprise Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") consolidated financial statements and have issued our report thereon dated September 30, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Cincinnati Children's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Cincinnati Children's internal control. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Cincinnati Children's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Cincinnati Children's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

September 30, 2021

Deloitte.

Deloitte & Touche LLP
50 W 5th Street
Suite 200
Cincinnati, OH 45202-3789
USA

Tel: +513 784 7100
Fax: +513 784 7204
www.deloitte.com

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of Cincinnati Children's major federal programs for the year ended June 30, 2021. Cincinnati Children's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of Cincinnati Children's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principals, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Cincinnati Children's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Cincinnati Children's compliance.

Opinion on Each Major Federal Program

In our opinion, Cincinnati Children's complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.

Report on Internal Control Over Compliance

Management of Cincinnati Children's is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Cincinnati Children's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of Cincinnati Children's as of and for the year ended June 30, 2021, and have issued our report thereon dated September 30, 2021, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Deloitte & Touche LLP

June 17, 2022

SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2021

PART I. SUMMARY OF AUDITOR'S RESULTS

Financial Statements:

Type of auditor's report issued:	Unmodified	
Internal control over financial reporting:		
Material weakness(es) identified?	______ Yes	X No
Significant deficiency(ies) identified?	______ Yes	X None reported
Noncompliance material to financial statements noted?	______ Yes	X No

Federal Awards:

Internal control over major programs:		
Material weakness(es) identified?	______ Yes	X No
Significant deficiency(ies) identified?	______ Yes	X None reported
Type of auditor's report issued on compliance for major programs:	Unmodified	
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	______ Yes	X No

Identification of Major Programs:

CFDA Number	Name of Federal Program or Cluster
Various	Research and Development*
93.498	COVID-19-Provider Relief Fund And American Rescue Plan (ARP) Distribution

* Cincinnati Children's has determined that its entire research and development program inclusive of all research and development grant activity should be considered clustered and as such, constitutes one major program.

Dollar threshold used to distinguish between Type A and Type B programs? Research and Development program tested as a single Type A program	$ 3,000,000

Auditee qualified as low-risk auditee?	X Yes	______ No

PART II. FINDINGS RELATED TO THE FINANCIAL STATEMENTS

None

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None